ClinicalTrials.gg
TerminatedNCT06964165Updated Nov 26, 2025Results posted

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

A Phase 2 interventional study of Niraparib and Carboplatin in Ovarian Neoplasms, sponsored by Tesaro, Inc.. Terminated at 21 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study stopped after meeting pre-specified futility criteria

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Apr 2022, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
26th of 44
36 · median 41
Started
2022
with 1 other
Phase 2
18 of 44
5 open now
Registered
44th of 44
by date
Lead sponsor
11 of 44
Tesaro, Inc.

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 26th largest by enrollment, is one of 2 that started in 2022, is one of 18 in phase 2, and was the 44th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

Keywords

  • Ovarian Cancer
  • Homologous Recombination Deficiency (HRD)
  • Interval debulking surgery (IDS)
  • Niraparib
  • Paclitaxel
  • Carboplatin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has newly diagnosed Stage III or IV ovarian, fallopian tube, or primary peritoneal cancer according to the International Federation of Gynecology and Obstetrics staging criteria.
  • Participants must provide sufficient tumor tissue at Prescreening and agree to undergo a central HRD tumor testing using a fully validated assay. The participants must be HRd as per central HRD tumor testing result for eligibility.

    1. Participants with a documented germline breast cancer susceptibility gene (BRCA) 1/2 deleterious or suspected deleterious mutations by Sponsor's permitted test (e.g., BRACAnalysis CDx) may be allowed to enroll prior to receiving the central test results, provided all inclusion criteria are met. However, tumor sample submitted by these participants will still be required for central HRD confirmation. The list of Sponsor's permitted tests will be provided by the Sponsor.
    2. All participants must agree to provide tumor tissue collected from IDS.
    3. Participant must provide 2 formalin-fixed paraffin-embedded tissue blocks (or slides if blocks are not available) with sufficient tumor content (as confirmed by the Sponsor's designated central and/or testing laboratory) for central HRD testing at Prescreening and for exploratory biomarker testing at Prescreening or Screening. If sufficient tumor tissue is provided at Prescreening, participants do not need to provide additional tissue at Screening.
  • Participant must have completed 1 run-in cycle of carboplatin-paclitaxel and not experienced disease progression after this treatment. Completion is defined as receiving ≥50% of the prescribed dose of therapy within 5 weeks.
  • Participant must not have known or uncontrolled to carboplatin and paclitaxel and their and no known pre-existing conditions that would preclude treatment with these agents.
  • Participant must not have known contraindication or uncontrolled hypersensitivity to niraparib and its excipients.
  • Participant must not have symptomatic ascites or pleural effusions as defined by the following criterion: presence of fluid in the abdominal or pleural cavities requiring removal within 1 week prior to signing the .
  • Participant must agree to complete Patient-reported outcome (PRO) and work productivity questionnaires throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Participant has low-grade or Grade 1 epithelial Ovarian Cancer (OC) or mucinous, germ cell, transitional cell, carcinosarcoma, or undifferentiated tumor.
  • Participant has to surgery.
  • Participant has a bowel obstruction by clinical symptoms or Computed tomography (CT) scan, subocclusive mesenteric disease, abdominal or gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess.
  • Participant has any known history or current diagnosis of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML).
  • Participant is at increased bleeding risk due to concurrent conditions (e.g., major injuries or major surgery within the past 28 days prior to the start of study treatment and/or history of hemorrhagic stroke, , subarachnoid hemorrhage, or hemorrhage within the past 3 months).
  • Participant is . Participants with splenectomy are allowed. Participants with known (HIV) are allowed if they meet all of the following criteria:

    1. Cluster of differentiation 4-positive T cell count ≥350/μL and viral load \<400 copies/mL
    2. No history of Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months prior to enrollment
    3. No history of HIV-associated for the past 5 years
    4. Concurrent antiretroviral therapy as per the most current National Institutes of Health Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV started >4 weeks prior to study enrollment
  • Participant received prior treatment for high-grade non-mucinous epithelial ovarian, fallopian tube, or peritoneal cancer (e.g., prior surgery, immunotherapy, anticancer therapy [with the exception of 1 run-in cycle of carboplatin-paclitaxel], or radiation therapy).
  • Participant has an active disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (e.g., thyroid hormone or insulin).
  • Participant is unable to swallow orally administered medication or has a gastrointestinal disorder likely to interfere with absorption of the study medication.
  • Participant received whole blood transfusions in the 2 weeks prior to entry to the study (packed red blood cells and transfusions are acceptable outside of 2 weeks prior to treatment).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort C (Niraparib)

    Drug: Niraparib

  • Experimental
    Cohort C (Carboplatin + Paclitaxel)

    Drug: Carboplatin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR)

    Pre-IDS unconfirmed ORR is defined as the percentage of participants with unconfirmed complete or partial response on study treatment pre-IDS as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters

    Time frame: Up to approximately 102 weeks

Secondary outcomes

  1. Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria

    Serum samples were collected to assess CA-125 progression based on the GCIG CA-125 response criteria, which is defined as follows: Criteria 1 - For participants with elevated CA-125 levels pre-treatment that reduced to the normal range during the study, progression is defined as CA-125 ≥2× Upper limit of normal (ULN) on 2 occasions at least 1 week apart.; Criteria 2 - For participants with elevated CA-125 levels pre-treatment that did not reduce to the normal range during the study, progression is defined as CA-125 ≥2× the nadir value on 2 occasions at least 1 week apart.; Criteria 3 - For participants with CA-125 levels in the normal range pre-treatment, progression is defined as CA-125 ≥2× ULN on 2 occasions at least 1 week apart.

    Time frame: At week 24

  2. Progression Free Survival (PFS)

    PFS is defined as the time from the date of treatment randomization to the date of first documentation of disease progression (PD) per RECIST v1.1 or death by any cause, whichever occurs first, as determined by the Investigator. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

    Time frame: Up to approximately 154 weeks

  3. Overall Survival (OS)

    OS is defined as the time from the date of treatment randomization to the date of death by any cause.

    Time frame: Up to approximately 154 weeks

  4. Time to First Subsequent Treatment (TFST)

    TFST is defined as the time from the date of treatment randomization to the date of first subsequent anticancer therapy or death.

    Time frame: Up to approximately 154 weeks

  5. Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

    The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants of cancer clinical studies. It characterizes the frequency and severity of adverse events using a standardized scoring system. Responses include 0 ("never" OR "none" OR "Not at all"); 1 ("Rarely" OR "Mild" OR "A little bit"); 2 ("Occasionally" OR "Moderate" OR "Somewhat"); 3 ("Frequently" OR "Severe" OR "Quite a bit") and 4 ("almost constantly" OR "very severe" OR "Very much"), with a higher score indicating a higher frequency and severity of adverse events.

    Time frame: Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8 and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).

  6. Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5

    The FACT-GP5 item is a single item from the FACT-G that assesses how bothersome the side effects of treatment are for participants with cancer. It evaluates the extent to which side effects of treatment are bothersome for cancer participants. This outcome is measured using a 5-category response scale, where responses include 0="Not at all," 1="A little bit," 2="Somewhat," 3="Quite a bit," and 4="Very much." A higher score on this measure indicates that the participant experiences a greater level of bother from the side effects of treatment.

    Time frame: Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8, and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks)

  7. Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire

    EORTC IL136 includes items from the EORTC QLQ-C30, a 30-item survey assessing health-related quality of life (HRQoL) in cancer patients, featuring 5 functional scales, 3 symptom scales, 6 single items, and a global health status/HRQoL scale. Functional and symptom scales/items are rated on 4-point scale with options "Not at all," "A little," "Quite a bit," and "Very much". 2 items measuring global health status/quality of life use a 7-point scale ranging from 1 ("Very Poor") to 7 ("Excellent"). Each item has a specific scoring system, and scores were transformed to a 0-100 scale, where higher scores on functional scales and global health status/HRQoL scale indicate better functioning or quality of life, while higher scores on symptom scales/items indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to Cycle 1 Day 1 (C1D1), including those from unscheduled visits.

    Time frame: Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).

  8. Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire

    The OC module (QLQ-OV28) supplements the QLQ-C30 and was designed for participants with local or advanced disease who receive treatment by surgery with or without chemotherapy. It consists of 28 items including 3 functional scales (body image, sexuality, attitude to disease/treatment burden) and 5 symptom scales/items (abdominal/gastrointestinal symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side effects, and hair loss). A subset of 9 questions will be utilized for this cohort, referred to as the EORTC IL137. The scoring approach is identical to the EORTC QLQ-C30. Scores are transformed to a 0-100 scale, where higher functional scale scores indicate better functioning, and higher symptom scale scores indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to C1D1, including unscheduled visits.

    Time frame: Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).

  9. Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

    Time frame: Up to approximately 154 weeks

  10. Number of Participants With Dose Modification Due to TEAEs

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with dose modifications : permanent discontinuation, dose reduction and treatment interruption/delay due to AEs is summarized.

    Time frame: Up to approximately 154 weeks

07

Results

Posted Jul 15, 2025

Participant flow

Participant flow — Overall Study
MilestonePlatinum-taxaneNiraparib
Started1719
Completed00
Not completed1719
Withdrew: Death44
Withdrew: Physician decision11
Withdrew: Withdrawal by subject02
Withdrew: Study terminated by sponsor1210
Withdrew: Participant discontinued due to relocation to a long-term care facility01
Withdrew: Participant removed due to non-compliance01

Outcome measures

PrimaryPre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR)

Pre-IDS unconfirmed ORR is defined as the percentage of participants with unconfirmed complete or partial response on study treatment pre-IDS as assessed per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by the Investigator. Complete Response (CR) is defined as disappearance of all target and non target lesions and any pathological lymph nodes must be \<10 millimeter (mm) in the short axis. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the baseline sum of the diameters

Time frame:
Up to approximately 102 weeks
Reported as:
Number · Percentage of Participants
Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR)
Percentage of ParticipantsPlatinum-taxaneNiraparib
Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR)70.6 (44.04 to 89.69)31.6 (16.34 to 67.71)
Statistical analysis
  • Platinum-taxane vs Niraparib · Difference in pre-ids orr: -39 · 80% CI -56.8 to -17.7
SecondaryNumber of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria

Serum samples were collected to assess CA-125 progression based on the GCIG CA-125 response criteria, which is defined as follows: Criteria 1 - For participants with elevated CA-125 levels pre-treatment that reduced to the normal range during the study, progression is defined as CA-125 ≥2× Upper limit of normal (ULN) on 2 occasions at least 1 week apart.; Criteria 2 - For participants with elevated CA-125 levels pre-treatment that did not reduce to the normal range during the study, progression is defined as CA-125 ≥2× the nadir value on 2 occasions at least 1 week apart.; Criteria 3 - For participants with CA-125 levels in the normal range pre-treatment, progression is defined as CA-125 ≥2× ULN on 2 occasions at least 1 week apart.

Time frame:
At week 24
Reported as:
Count of participants · Participants
Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria
ParticipantsPlatinum-taxaneNiraparib
Criteria 100
Criteria 200
Criteria 300
SecondaryProgression Free Survival (PFS)

PFS is defined as the time from the date of treatment randomization to the date of first documentation of disease progression (PD) per RECIST v1.1 or death by any cause, whichever occurs first, as determined by the Investigator. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.

Time frame:
Up to approximately 154 weeks

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

OS is defined as the time from the date of treatment randomization to the date of death by any cause.

Time frame:
Up to approximately 154 weeks

No measurements were reported for this outcome.

SecondaryTime to First Subsequent Treatment (TFST)

TFST is defined as the time from the date of treatment randomization to the date of first subsequent anticancer therapy or death.

Time frame:
Up to approximately 154 weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants of cancer clinical studies. It characterizes the frequency and severity of adverse events using a standardized scoring system. Responses include 0 ("never" OR "none" OR "Not at all"); 1 ("Rarely" OR "Mild" OR "A little bit"); 2 ("Occasionally" OR "Moderate" OR "Somewhat"); 3 ("Frequently" OR "Severe" OR "Quite a bit") and 4 ("almost constantly" OR "very severe" OR "Very much"), with a higher score indicating a higher frequency and severity of adverse events.

Time frame:
Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8 and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Reported as:
Count of participants · Participants
Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
ParticipantsPlatinum-taxaneNiraparib
Probs Tasting Food/Drink, Baseline, Severity, 0=None109
Probs Tasting Food/Drink, Baseline, Severity, 1=Mild34
Probs Tasting Food/Drink, Baseline, Severity, 2=Moderate13
Probs Tasting Food/Drink, Baseline, Severity, 3=Severe01
Probs Tasting Food/Drink, Baseline, Severity, 4=Very severe00
Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 0=None67
Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 1=Mild35
Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 2=Moderate22
Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 3=Severe01
Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 4=Very severe00
Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 0=None126
Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 1=Mild15
Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 2=Moderate12
Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 3=Severe00
Probs Tasting Food/Drink, Cycle 1 Day 15, Severity, 4=Very severe00
Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 0=None98
Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 1=Mild24
Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 2=Moderate01
Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 3=Severe01
Probs Tasting Food/Drink, Cycle 2 Day 1, Severity, 4=Very severe00
Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 0=None66
Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 1=Mild34
Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 2=Moderate10
Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 3=Severe11
Probs Tasting Food/Drink, Cycle 2 Day 8, Severity, 4=Very severe00
Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 0=None810
Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 1=Mild53
Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 2=Moderate00
Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 3=Severe01
Probs Tasting Food/Drink, Cycle 2 Day 15, Severity, 4=Very severe00
Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 0=None128
Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 1=Mild24
Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 2=Moderate01
Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 3=Severe01
Probs Tasting Food/Drink, Cycle 3 Day 1, Severity, 4=Very severe00
Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 0=None16
Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 1=Mild33
Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 2=Moderate40
Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 3=Severe21
Probs Tasting Food/Drink, Cycle 3 Day 8, Severity, 4=Very severe00
Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 0=None34
Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 1=Mild23
Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 2=Moderate00
Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 3=Severe00
Probs Tasting Food/Drink, Cycle 3 Day 15, Severity, 4=Very severe00
Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 0=None10
Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 1=Mild11
Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 2=Moderate00
Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 3=Severe00
Probs Tasting Food/Drink, Pre-IDS Evaluation, Severity, 4=Very severe00
Probs Tasting Food/Drink, End Of Treatment, Severity, 0=None—2
Probs Tasting Food/Drink, End Of Treatment, Severity, 1=Mild—3
Probs Tasting Food/Drink, End Of Treatment, Severity, 2=Moderate—0
Probs Tasting Food/Drink, End Of Treatment, Severity, 3=Severe—0
Probs Tasting Food/Drink, End Of Treatment, Severity, 4=Very severe—0
Nausea, Baseline, Severity, 0=None12
Nausea, Baseline, Severity, 1=Mild55
Nausea, Baseline, Severity, 2=Moderate11
Nausea, Baseline, Severity, 3=Severe00
Nausea, Baseline, Severity, 4=Very severe01
Nausea, Baseline, Frequency, 0=Never78
Nausea, Baseline, Frequency, 1=Rarely65
Nausea, Baseline, Frequency, 2=Occasionally14
Nausea, Baseline, Frequency, 3=Frequently00
Nausea, Baseline, Frequency, 4=Almost constantly00
Nausea, Cycle 1 Day 8, Severity, 0=None10
Nausea, Cycle 1 Day 8, Severity, 1=Mild32
Nausea, Cycle 1 Day 8, Severity, 2=Moderate53
Nausea, Cycle 1 Day 8, Severity, 3=Severe02
Nausea, Cycle 1 Day 8, Severity, 4=Very severe00
Nausea, Cycle 1 Day 8, Frequency, 0=Never28
Nausea, Cycle 1 Day 8, Frequency, 1=Rarely42
Nausea, Cycle 1 Day 8, Frequency, 2=Occasionally43
Nausea, Cycle 1 Day 8, Frequency, 3=Frequently11
Nausea, Cycle 1 Day 8, Frequency, 4=Almost constantly01
Nausea, Cycle 1 Day 15, Severity, 0=None10
Nausea, Cycle 1 Day 15, Severity, 1=Mild32
Nausea, Cycle 1 Day 15, Severity, 2=Moderate23
Nausea, Cycle 1 Day 15, Severity, 3=Severe01
Nausea, Cycle 1 Day 15, Severity, 4=Very severe00
Nausea, Cycle 1 Day 15, Frequency, 0=Never87
Nausea, Cycle 1 Day 15, Frequency, 1=Rarely32
Nausea, Cycle 1 Day 15, Frequency, 2=Occasionally33
Nausea, Cycle 1 Day 15, Frequency, 3=Frequently01
Nausea, Cycle 1 Day 15, Frequency, 4=Almost constantly00
Nausea, Cycle 2 Day 1, Severity, 0=None11
Nausea, Cycle 2 Day 1, Severity, 1=Mild03
Nausea, Cycle 2 Day 1, Severity, 2=Moderate11
Nausea, Cycle 2 Day 1, Severity, 3=Severe02
Nausea, Cycle 2 Day 1, Severity, 4=Very severe00
Nausea, Cycle 2 Day 1, Frequency, 0=Never97
Nausea, Cycle 2 Day 1, Frequency, 1=Rarely23
Nausea, Cycle 2 Day 1, Frequency, 2=Occasionally03
Nausea, Cycle 2 Day 1, Frequency, 3=Frequently00
Nausea, Cycle 2 Day 1, Frequency, 4=Almost constantly01
Nausea, Cycle 2 Day 8, Severity, 0=None12
Nausea, Cycle 2 Day 8, Severity, 1=Mild41
Nausea, Cycle 2 Day 8, Severity, 2=Moderate01
Nausea, Cycle 2 Day 8, Severity, 3=Severe01
Nausea, Cycle 2 Day 8, Severity, 4=Very severe00
Nausea, Cycle 2 Day 8, Frequency, 0=Never66
Nausea, Cycle 2 Day 8, Frequency, 1=Rarely33
Nausea, Cycle 2 Day 8, Frequency, 2=Occasionally21
Nausea, Cycle 2 Day 8, Frequency, 3=Frequently01
Nausea, Cycle 2 Day 8, Frequency, 4=Almost constantly00
Nausea, Cycle 2 Day 15, Severity, 0=None02
Nausea, Cycle 2 Day 15, Severity, 1=Mild21
Nausea, Cycle 2 Day 15, Severity, 2=Moderate02
Nausea, Cycle 2 Day 15, Severity, 3=Severe01
Nausea, Cycle 2 Day 15, Severity, 4=Very severe00
Nausea, Cycle 2 Day 15, Frequency, 0=Never118
Nausea, Cycle 2 Day 15, Frequency, 1=Rarely13
Nausea, Cycle 2 Day 15, Frequency, 2=Occasionally11
Nausea, Cycle 2 Day 15, Frequency, 3=Frequently02
Nausea, Cycle 2 Day 15, Frequency, 4=Almost constantly00
Nausea, Cycle 3 Day 1, Severity, 0=None00
Nausea, Cycle 3 Day 1, Severity, 1=Mild23
Nausea, Cycle 3 Day 1, Severity, 2=Moderate01
Nausea, Cycle 3 Day 1, Severity, 3=Severe01
Nausea, Cycle 3 Day 1, Severity, 4=Very severe01
Nausea, Cycle 3 Day 1, Frequency, 0=Never128
Nausea, Cycle 3 Day 1, Frequency, 1=Rarely23
Nausea, Cycle 3 Day 1, Frequency, 2=Occasionally00
Nausea, Cycle 3 Day 1, Frequency, 3=Frequently02
Nausea, Cycle 3 Day 1, Frequency, 4=Almost constantly01
Nausea, Cycle 3 Day 8, Severity, 0=None11
Nausea, Cycle 3 Day 8, Severity, 1=Mild12
Nausea, Cycle 3 Day 8, Severity, 2=Moderate21
Nausea, Cycle 3 Day 8, Severity, 3=Severe11
Nausea, Cycle 3 Day 8, Severity, 4=Very severe00
Nausea, Cycle 3 Day 8, Frequency, 0=Never55
Nausea, Cycle 3 Day 8, Frequency, 1=Rarely22
Nausea, Cycle 3 Day 8, Frequency, 2=Occasionally02
Nausea, Cycle 3 Day 8, Frequency, 3=Frequently31
Nausea, Cycle 3 Day 8, Frequency, 4=Almost constantly00
Nausea, Cycle 3 Day 15, Severity, 0=None02
Nausea, Cycle 3 Day 15, Severity, 1=Mild30
Nausea, Cycle 3 Day 15, Severity, 2=Moderate11
Nausea, Cycle 3 Day 15, Severity, 3=Severe00
Nausea, Cycle 3 Day 15, Severity, 4=Very severe00
Nausea, Cycle 3 Day 15, Frequency, 0=Never14
Nausea, Cycle 3 Day 15, Frequency, 1=Rarely32
Nausea, Cycle 3 Day 15, Frequency, 2=Occasionally11
Nausea, Cycle 3 Day 15, Frequency, 3=Frequently00
Nausea, Cycle 3 Day 15, Frequency, 4=Almost constantly00
Nausea, Pre-IDS Evaluation, Frequency, 0=Never21
Nausea, Pre-IDS Evaluation, Frequency, 1=Rarely00
Nausea, Pre-IDS Evaluation, Frequency, 2=Occasionally00
Nausea, Pre-IDS Evaluation, Frequency, 3=Frequently00
Nausea, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Nausea, End Of Treatment, Severity, 0=None—1
Nausea, End Of Treatment, Severity, 1=Mild—3
Nausea, End Of Treatment, Severity, 2=Moderate—0
Nausea, End Of Treatment, Severity, 3=Severe—0
Nausea, End Of Treatment, Severity, 4=Very severe—0
Nausea, End Of Treatment, Frequency, 0=Never—1
Nausea, End Of Treatment, Frequency, 1=Rarely—3
Nausea, End Of Treatment, Frequency, 2=Occasionally—1
Nausea, End Of Treatment, Frequency, 3=Frequently—0
Nausea, End Of Treatment, Frequency, 4=Almost constantly—0
Vomiting, Baseline, Severity, 0=None00
Vomiting, Baseline, Severity, 1=Mild10
Vomiting, Baseline, Severity, 2=Moderate01
Vomiting, Baseline, Severity, 3=Severe00
Vomiting, Baseline, Severity, 4=Very severe00
Vomiting, Baseline, Frequency, 0=Never1316
Vomiting, Baseline, Frequency, 1=Rarely10
Vomiting, Baseline, Frequency, 2=Occasionally01
Vomiting, Baseline, Frequency, 3=Frequently00
Vomiting, Baseline, Frequency, 4=Almost constantly00
Vomiting, Cycle 1 Day 8, Severity, 0=None00
Vomiting, Cycle 1 Day 8, Severity, 1=Mild12
Vomiting, Cycle 1 Day 8, Severity, 2=Moderate01
Vomiting, Cycle 1 Day 8, Severity, 3=Severe00
Vomiting, Cycle 1 Day 8, Severity, 4=Very severe00
Vomiting, Cycle 1 Day 8, Frequency, 0=Never1012
Vomiting, Cycle 1 Day 8, Frequency, 1=Rarely12
Vomiting, Cycle 1 Day 8, Frequency, 2=Occasionally01
Vomiting, Cycle 1 Day 8, Frequency, 3=Frequently00
Vomiting, Cycle 1 Day 8, Frequency, 4=Almost constantly00
Vomiting, Cycle 1 Day 15, Severity, 0=None—0
Vomiting, Cycle 1 Day 15, Severity, 1=Mild—1
Vomiting, Cycle 1 Day 15, Severity, 2=Moderate—0
Vomiting, Cycle 1 Day 15, Severity, 3=Severe—0
Vomiting, Cycle 1 Day 15, Severity, 4=Very severe—0
Vomiting, Cycle 1 Day 15, Frequency, 0=Never1412
Vomiting, Cycle 1 Day 15, Frequency, 1=Rarely01
Vomiting, Cycle 1 Day 15, Frequency, 2=Occasionally00
Vomiting, Cycle 1 Day 15, Frequency, 3=Frequently00
Vomiting, Cycle 1 Day 15, Frequency, 4=Almost constantly00
Vomiting, Cycle 2 Day 1, Severity, 0=None—0
Vomiting, Cycle 2 Day 1, Severity, 1=Mild—1
Vomiting, Cycle 2 Day 1, Severity, 2=Moderate—1
Vomiting, Cycle 2 Day 1, Severity, 3=Severe—0
Vomiting, Cycle 2 Day 1, Severity, 4=Very severe—0
Vomiting, Cycle 2 Day 1, Frequency, 0=Never1112
Vomiting, Cycle 2 Day 1, Frequency, 1=Rarely02
Vomiting, Cycle 2 Day 1, Frequency, 2=Occasionally00
Vomiting, Cycle 2 Day 1, Frequency, 3=Frequently00
Vomiting, Cycle 2 Day 1, Frequency, 4=Almost constantly00
Vomiting, Cycle 2 Day 8, Severity, 0=None00
Vomiting, Cycle 2 Day 8, Severity, 1=Mild11
Vomiting, Cycle 2 Day 8, Severity, 2=Moderate01
Vomiting, Cycle 2 Day 8, Severity, 3=Severe00
Vomiting, Cycle 2 Day 8, Severity, 4=Very severe00
Vomiting, Cycle 2 Day 8, Frequency, 0=Never109
Vomiting, Cycle 2 Day 8, Frequency, 1=Rarely12
Vomiting, Cycle 2 Day 8, Frequency, 2=Occasionally00
Vomiting, Cycle 2 Day 8, Frequency, 3=Frequently00
Vomiting, Cycle 2 Day 8, Frequency, 4=Almost constantly00
Vomiting, Cycle 2 Day 15, Severity, 0=None01
Vomiting, Cycle 2 Day 15, Severity, 1=Mild10
Vomiting, Cycle 2 Day 15, Severity, 2=Moderate00
Vomiting, Cycle 2 Day 15, Severity, 3=Severe00
Vomiting, Cycle 2 Day 15, Severity, 4=Very severe00
Vomiting, Cycle 2 Day 15, Frequency, 0=Never1213
Vomiting, Cycle 2 Day 15, Frequency, 1=Rarely11
Vomiting, Cycle 2 Day 15, Frequency, 2=Occasionally00
Vomiting, Cycle 2 Day 15, Frequency, 3=Frequently00
Vomiting, Cycle 2 Day 15, Frequency, 4=Almost constantly00
Vomiting, Cycle 3 Day 1, Severity, 0=None—0
Vomiting, Cycle 3 Day 1, Severity, 1=Mild—1
Vomiting, Cycle 3 Day 1, Severity, 2=Moderate—0
Vomiting, Cycle 3 Day 1, Severity, 3=Severe—2
Vomiting, Cycle 3 Day 1, Severity, 4=Very severe—0
Vomiting, Cycle 3 Day 1, Frequency, 0=Never1411
Vomiting, Cycle 3 Day 1, Frequency, 1=Rarely02
Vomiting, Cycle 3 Day 1, Frequency, 2=Occasionally00
Vomiting, Cycle 3 Day 1, Frequency, 3=Frequently01
Vomiting, Cycle 3 Day 1, Frequency, 4=Almost constantly00
Vomiting, Cycle 3 Day 8, Severity, 0=None00
Vomiting, Cycle 3 Day 8, Severity, 1=Mild00
Vomiting, Cycle 3 Day 8, Severity, 2=Moderate11
Vomiting, Cycle 3 Day 8, Severity, 3=Severe00
Vomiting, Cycle 3 Day 8, Severity, 4=Very severe00
Vomiting, Cycle 3 Day 8, Frequency, 0=Never99
Vomiting, Cycle 3 Day 8, Frequency, 1=Rarely00
Vomiting, Cycle 3 Day 8, Frequency, 2=Occasionally11
Vomiting, Cycle 3 Day 8, Frequency, 3=Frequently00
Vomiting, Cycle 3 Day 8, Frequency, 4=Almost constantly00
Vomiting, Cycle 3 Day 15, Severity, 0=None—1
Vomiting, Cycle 3 Day 15, Severity, 1=Mild—0
Vomiting, Cycle 3 Day 15, Severity, 2=Moderate—1
Vomiting, Cycle 3 Day 15, Severity, 3=Severe—0
Vomiting, Cycle 3 Day 15, Severity, 4=Very severe—0
Vomiting, Cycle 3 Day 15, Frequency, 0=Never55
Vomiting, Cycle 3 Day 15, Frequency, 1=Rarely01
Vomiting, Cycle 3 Day 15, Frequency, 2=Occasionally01
Vomiting, Cycle 3 Day 15, Frequency, 3=Frequently00
Vomiting, Cycle 3 Day 15, Frequency, 4=Almost constantly00
Vomiting, Pre-IDS Evaluation, Frequency, 0=Never21
Vomiting, Pre-IDS Evaluation, Frequency, 1=Rarely00
Vomiting, Pre-IDS Evaluation, Frequency, 2=Occasionally00
Vomiting, Pre-IDS Evaluation, Frequency, 3=Frequently00
Vomiting, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Vomiting, End Of Treatment, Severity, 0=None—0
Vomiting, End Of Treatment, Severity, 1=Mild—1
Vomiting, End Of Treatment, Severity, 2=Moderate—0
Vomiting, End Of Treatment, Severity, 3=Severe—0
Vomiting, End Of Treatment, Severity, 4=Very severe—0
Vomiting, End Of Treatment, Frequency, 0=Never—4
Vomiting, End Of Treatment, Frequency, 1=Rarely—0
Vomiting, End Of Treatment, Frequency, 2=Occasionally—1
Vomiting, End Of Treatment, Frequency, 3=Frequently—0
Vomiting, End Of Treatment, Frequency, 4=Almost constantly—0
Bloating of Abdomen, Baseline, Severity, 0=None00
Bloating of Abdomen, Baseline, Severity, 1=Mild75
Bloating of Abdomen, Baseline, Severity, 2=Moderate33
Bloating of Abdomen, Baseline, Severity, 3=Severe10
Bloating of Abdomen, Baseline, Severity, 4=Very severe00
Bloating of Abdomen, Baseline, Frequency, 0=Never39
Bloating of Abdomen, Baseline, Frequency, 1=Rarely53
Bloating of Abdomen, Baseline, Frequency, 2=Occasionally34
Bloating of Abdomen, Baseline, Frequency, 3=Frequently11
Bloating of Abdomen, Baseline, Frequency, 4=Almost constantly20
Bloating of Abdomen, Cycle 1 Day 8, Severity, 0=None00
Bloating of Abdomen, Cycle 1 Day 8, Severity, 1=Mild35
Bloating of Abdomen, Cycle 1 Day 8, Severity, 2=Moderate43
Bloating of Abdomen, Cycle 1 Day 8, Severity, 3=Severe11
Bloating of Abdomen, Cycle 1 Day 8, Severity, 4=Very severe00
Bloating of Abdomen, Cycle 1 Day 8, Frequency, 0=Never36
Bloating of Abdomen, Cycle 1 Day 8, Frequency, 1=Rarely13
Bloating of Abdomen, Cycle 1 Day 8, Frequency, 2=Occasionally54
Bloating of Abdomen, Cycle 1 Day 8, Frequency, 3=Frequently10
Bloating of Abdomen, Cycle 1 Day 8, Frequency, 4=Almost constantly12
Bloating of Abdomen, Cycle 1 Day 15, Severity, 0=None00
Bloating of Abdomen, Cycle 1 Day 15, Severity, 1=Mild52
Bloating of Abdomen, Cycle 1 Day 15, Severity, 2=Moderate35
Bloating of Abdomen, Cycle 1 Day 15, Severity, 3=Severe01
Bloating of Abdomen, Cycle 1 Day 15, Severity, 4=Very severe01
Bloating of Abdomen, Cycle 1 Day 15, Frequency, 0=Never64
Bloating of Abdomen, Cycle 1 Day 15, Frequency, 1=Rarely53
Bloating of Abdomen, Cycle 1 Day 15, Frequency, 2=Occasionally04
Bloating of Abdomen, Cycle 1 Day 15, Frequency, 3=Frequently20
Bloating of Abdomen, Cycle 1 Day 15, Frequency, 4=Almost constantly12
Bloating of Abdomen, Cycle 2 Day 1, Severity, 0=None00
Bloating of Abdomen, Cycle 2 Day 1, Severity, 1=Mild73
Bloating of Abdomen, Cycle 2 Day 1, Severity, 2=Moderate03
Bloating of Abdomen, Cycle 2 Day 1, Severity, 3=Severe00
Bloating of Abdomen, Cycle 2 Day 1, Severity, 4=Very severe00
Bloating of Abdomen, Cycle 2 Day 1, Frequency, 0=Never48
Bloating of Abdomen, Cycle 2 Day 1, Frequency, 1=Rarely63
Bloating of Abdomen, Cycle 2 Day 1, Frequency, 2=Occasionally13
Bloating of Abdomen, Cycle 2 Day 1, Frequency, 3=Frequently00
Bloating of Abdomen, Cycle 2 Day 1, Frequency, 4=Almost constantly00
Bloating of Abdomen, Cycle 2 Day 8, Severity, 0=None00
Bloating of Abdomen, Cycle 2 Day 8, Severity, 1=Mild44
Bloating of Abdomen, Cycle 2 Day 8, Severity, 2=Moderate23
Bloating of Abdomen, Cycle 2 Day 8, Severity, 3=Severe20
Bloating of Abdomen, Cycle 2 Day 8, Severity, 4=Very severe00
Bloating of Abdomen, Cycle 2 Day 8, Frequency, 0=Never34
Bloating of Abdomen, Cycle 2 Day 8, Frequency, 1=Rarely34
Bloating of Abdomen, Cycle 2 Day 8, Frequency, 2=Occasionally32
Bloating of Abdomen, Cycle 2 Day 8, Frequency, 3=Frequently21
Bloating of Abdomen, Cycle 2 Day 8, Frequency, 4=Almost constantly00
Bloating of Abdomen, Cycle 2 Day 15, Severity, 0=None01
Bloating of Abdomen, Cycle 2 Day 15, Severity, 1=Mild53
Bloating of Abdomen, Cycle 2 Day 15, Severity, 2=Moderate22
Bloating of Abdomen, Cycle 2 Day 15, Severity, 3=Severe03
Bloating of Abdomen, Cycle 2 Day 15, Severity, 4=Very severe00
Bloating of Abdomen, Cycle 2 Day 15, Frequency, 0=Never65
Bloating of Abdomen, Cycle 2 Day 15, Frequency, 1=Rarely24
Bloating of Abdomen, Cycle 2 Day 15, Frequency, 2=Occasionally41
Bloating of Abdomen, Cycle 2 Day 15, Frequency, 3=Frequently14
Bloating of Abdomen, Cycle 2 Day 15, Frequency, 4=Almost constantly00
Bloating of Abdomen, Cycle 3 Day 1, Severity, 0=None10
Bloating of Abdomen, Cycle 3 Day 1, Severity, 1=Mild46
Bloating of Abdomen, Cycle 3 Day 1, Severity, 2=Moderate23
Bloating of Abdomen, Cycle 3 Day 1, Severity, 3=Severe01
Bloating of Abdomen, Cycle 3 Day 1, Severity, 4=Very severe00
Bloating of Abdomen, Cycle 3 Day 1, Frequency, 0=Never74
Bloating of Abdomen, Cycle 3 Day 1, Frequency, 1=Rarely25
Bloating of Abdomen, Cycle 3 Day 1, Frequency, 2=Occasionally24
Bloating of Abdomen, Cycle 3 Day 1, Frequency, 3=Frequently31
Bloating of Abdomen, Cycle 3 Day 1, Frequency, 4=Almost constantly00
Bloating of Abdomen, Cycle 3 Day 8, Severity, 0=None10
Bloating of Abdomen, Cycle 3 Day 8, Severity, 1=Mild25
Bloating of Abdomen, Cycle 3 Day 8, Severity, 2=Moderate23
Bloating of Abdomen, Cycle 3 Day 8, Severity, 3=Severe11
Bloating of Abdomen, Cycle 3 Day 8, Severity, 4=Very severe00
Bloating of Abdomen, Cycle 3 Day 8, Frequency, 0=Never41
Bloating of Abdomen, Cycle 3 Day 8, Frequency, 1=Rarely24
Bloating of Abdomen, Cycle 3 Day 8, Frequency, 2=Occasionally33
Bloating of Abdomen, Cycle 3 Day 8, Frequency, 3=Frequently02
Bloating of Abdomen, Cycle 3 Day 8, Frequency, 4=Almost constantly10
Bloating of Abdomen, Cycle 3 Day 15, Severity, 0=None10
Bloating of Abdomen, Cycle 3 Day 15, Severity, 1=Mild13
Bloating of Abdomen, Cycle 3 Day 15, Severity, 2=Moderate02
Bloating of Abdomen, Cycle 3 Day 15, Severity, 3=Severe00
Bloating of Abdomen, Cycle 3 Day 15, Severity, 4=Very severe00
Bloating of Abdomen, Cycle 3 Day 15, Frequency, 0=Never32
Bloating of Abdomen, Cycle 3 Day 15, Frequency, 1=Rarely13
Bloating of Abdomen, Cycle 3 Day 15, Frequency, 2=Occasionally10
Bloating of Abdomen, Cycle 3 Day 15, Frequency, 3=Frequently02
Bloating of Abdomen, Cycle 3 Day 15, Frequency, 4=Almost constantly00
Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 0=Never21
Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 1=Rarely00
Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 2=Occasionally00
Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 3=Frequently00
Bloating of Abdomen, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Bloating of Abdomen, End Of Treatment, Severity, 0=None—0
Bloating of Abdomen, End Of Treatment, Severity, 1=Mild—2
Bloating of Abdomen, End Of Treatment, Severity, 2=Moderate—1
Bloating of Abdomen, End Of Treatment, Severity, 3=Severe—1
Bloating of Abdomen, End Of Treatment, Severity, 4=Very severe—0
Bloating of Abdomen, End Of Treatment, Frequency, 0=Never—1
Bloating of Abdomen, End Of Treatment, Frequency, 1=Rarely—1
Bloating of Abdomen, End Of Treatment, Frequency, 2=Occasionally—1
Bloating of Abdomen, End Of Treatment, Frequency, 3=Frequently—1
Bloating of Abdomen, End Of Treatment, Frequency, 4=Almost constantly—1
Constipation, Baseline, Severity, 0=None89
Constipation, Baseline, Severity, 1=Mild36
Constipation, Baseline, Severity, 2=Moderate12
Constipation, Baseline, Severity, 3=Severe10
Constipation, Baseline, Severity, 4=Very severe10
Constipation, Cycle 1 Day 8, Severity, 0=None58
Constipation, Cycle 1 Day 8, Severity, 1=Mild02
Constipation, Cycle 1 Day 8, Severity, 2=Moderate32
Constipation, Cycle 1 Day 8, Severity, 3=Severe33
Constipation, Cycle 1 Day 8, Severity, 4=Very severe00
Constipation, Cycle 1 Day 15, Severity, 0=None106
Constipation, Cycle 1 Day 15, Severity, 1=Mild44
Constipation, Cycle 1 Day 15, Severity, 2=Moderate01
Constipation, Cycle 1 Day 15, Severity, 3=Severe01
Constipation, Cycle 1 Day 15, Severity, 4=Very severe01
Constipation, Cycle 2 Day 1, Severity, 0=None86
Constipation, Cycle 2 Day 1, Severity, 1=Mild25
Constipation, Cycle 2 Day 1, Severity, 2=Moderate12
Constipation, Cycle 2 Day 1, Severity, 3=Severe00
Constipation, Cycle 2 Day 1, Severity, 4=Very severe01
Constipation, Cycle 2 Day 8, Severity, 0=None65
Constipation, Cycle 2 Day 8, Severity, 1=Mild24
Constipation, Cycle 2 Day 8, Severity, 2=Moderate22
Constipation, Cycle 2 Day 8, Severity, 3=Severe10
Constipation, Cycle 2 Day 8, Severity, 4=Very severe00
Constipation, Cycle 2 Day 15, Severity, 0=None108
Constipation, Cycle 2 Day 15, Severity, 1=Mild32
Constipation, Cycle 2 Day 15, Severity, 2=Moderate03
Constipation, Cycle 2 Day 15, Severity, 3=Severe01
Constipation, Cycle 2 Day 15, Severity, 4=Very severe00
Constipation, Cycle 3 Day 1, Severity, 0=None116
Constipation, Cycle 3 Day 1, Severity, 1=Mild21
Constipation, Cycle 3 Day 1, Severity, 2=Moderate15
Constipation, Cycle 3 Day 1, Severity, 3=Severe01
Constipation, Cycle 3 Day 1, Severity, 4=Very severe01
Constipation, Cycle 3 Day 8, Severity, 0=None44
Constipation, Cycle 3 Day 8, Severity, 1=Mild52
Constipation, Cycle 3 Day 8, Severity, 2=Moderate12
Constipation, Cycle 3 Day 8, Severity, 3=Severe02
Constipation, Cycle 3 Day 8, Severity, 4=Very severe00
Constipation, Cycle 3 Day 15, Severity, 0=None43
Constipation, Cycle 3 Day 15, Severity, 1=Mild13
Constipation, Cycle 3 Day 15, Severity, 2=Moderate01
Constipation, Cycle 3 Day 15, Severity, 3=Severe00
Constipation, Cycle 3 Day 15, Severity, 4=Very severe00
Constipation, Pre-IDS Evaluation, Severity, 0=None20
Constipation, Pre-IDS Evaluation, Severity, 1=Mild00
Constipation, Pre-IDS Evaluation, Severity, 2=Moderate00
Constipation, Pre-IDS Evaluation, Severity, 3=Severe00
Constipation, Pre-IDS Evaluation, Severity, 4=Very severe01
Constipation, End Of Treatment, Severity, 0=None—2
Constipation, End Of Treatment, Severity, 1=Mild—3
Constipation, End Of Treatment, Severity, 2=Moderate—0
Constipation, End Of Treatment, Severity, 3=Severe—0
Constipation, End Of Treatment, Severity, 4=Very severe—0
Loose/Watery Stools, Baseline, Frequency, 0=Never810
Loose/Watery Stools, Baseline, Frequency, 1=Rarely25
Loose/Watery Stools, Baseline, Frequency, 2=Occasionally41
Loose/Watery Stools, Baseline, Frequency, 3=Frequently01
Loose/Watery Stools, Baseline, Frequency, 4=Almost constantly00
Loose/Watery Stools, Cycle 1 Day 8, Frequency, 0=Never811
Loose/Watery Stools, Cycle 1 Day 8, Frequency, 1=Rarely13
Loose/Watery Stools, Cycle 1 Day 8, Frequency, 2=Occasionally21
Loose/Watery Stools, Cycle 1 Day 8, Frequency, 3=Frequently00
Loose/Watery Stools, Cycle 1 Day 8, Frequency, 4=Almost constantly00
Loose/Watery Stools, Cycle 1 Day 15, Frequency, 0=Never1110
Loose/Watery Stools, Cycle 1 Day 15, Frequency, 1=Rarely22
Loose/Watery Stools, Cycle 1 Day 15, Frequency, 2=Occasionally11
Loose/Watery Stools, Cycle 1 Day 15, Frequency, 3=Frequently00
Loose/Watery Stools, Cycle 1 Day 15, Frequency, 4=Almost constantly00
Loose/Watery Stools, Cycle 2 Day 1, Frequency, 0=Never912
Loose/Watery Stools, Cycle 2 Day 1, Frequency, 1=Rarely01
Loose/Watery Stools, Cycle 2 Day 1, Frequency, 2=Occasionally10
Loose/Watery Stools, Cycle 2 Day 1, Frequency, 3=Frequently11
Loose/Watery Stools, Cycle 2 Day 1, Frequency, 4=Almost constantly00
Loose/Watery Stools, Cycle 2 Day 8, Frequency, 0=Never79
Loose/Watery Stools, Cycle 2 Day 8, Frequency, 1=Rarely22
Loose/Watery Stools, Cycle 2 Day 8, Frequency, 2=Occasionally20
Loose/Watery Stools, Cycle 2 Day 8, Frequency, 3=Frequently00
Loose/Watery Stools, Cycle 2 Day 8, Frequency, 4=Almost constantly00
Loose/Watery Stools, Cycle 2 Day 15, Frequency, 0=Never812
Loose/Watery Stools, Cycle 2 Day 15, Frequency, 1=Rarely11
Loose/Watery Stools, Cycle 2 Day 15, Frequency, 2=Occasionally31
Loose/Watery Stools, Cycle 2 Day 15, Frequency, 3=Frequently10
Loose/Watery Stools, Cycle 2 Day 15, Frequency, 4=Almost constantly00
Loose/Watery Stools, Cycle 3 Day 1, Frequency, 0=Never812
Loose/Watery Stools, Cycle 3 Day 1, Frequency, 1=Rarely41
Loose/Watery Stools, Cycle 3 Day 1, Frequency, 2=Occasionally01
Loose/Watery Stools, Cycle 3 Day 1, Frequency, 3=Frequently10
Loose/Watery Stools, Cycle 3 Day 1, Frequency, 4=Almost constantly10
Loose/Watery Stools, Cycle 3 Day 8, Frequency, 0=Never78
Loose/Watery Stools, Cycle 3 Day 8, Frequency, 1=Rarely01
Loose/Watery Stools, Cycle 3 Day 8, Frequency, 2=Occasionally00
Loose/Watery Stools, Cycle 3 Day 8, Frequency, 3=Frequently21
Loose/Watery Stools, Cycle 3 Day 8, Frequency, 4=Almost constantly10
Loose/Watery Stools, Cycle 3 Day 15, Frequency, 0=Never15
Loose/Watery Stools, Cycle 3 Day 15, Frequency, 1=Rarely22
Loose/Watery Stools, Cycle 3 Day 15, Frequency, 2=Occasionally20
Loose/Watery Stools, Cycle 3 Day 15, Frequency, 3=Frequently00
Loose/Watery Stools, Cycle 3 Day 15, Frequency, 4=Almost constantly00
Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 0=Never21
Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 1=Rarely00
Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 2=Occasionally00
Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 3=Frequently00
Loose/Watery Stools, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Loose/Watery Stools, End Of Treatment, Frequency, 0=Never—3
Loose/Watery Stools, End Of Treatment, Frequency, 1=Rarely—1
Loose/Watery Stools, End Of Treatment, Frequency, 2=Occasionally—1
Loose/Watery Stools, End Of Treatment, Frequency, 3=Frequently—0
Loose/Watery Stools, End Of Treatment, Frequency, 4=Almost constantly—0
Pain in the Abdomen, Baseline, Severity, 0=None01
Pain in the Abdomen, Baseline, Severity, 1=Mild65
Pain in the Abdomen, Baseline, Severity, 2=Moderate64
Pain in the Abdomen, Baseline, Severity, 3=Severe01
Pain in the Abdomen, Baseline, Severity, 4=Very severe00
Pain in the Abdomen, Baseline, Frequency, 0=Never26
Pain in the Abdomen, Baseline, Frequency, 1=Rarely65
Pain in the Abdomen, Baseline, Frequency, 2=Occasionally34
Pain in the Abdomen, Baseline, Frequency, 3=Frequently22
Pain in the Abdomen, Baseline, Frequency, 4=Almost constantly10
Pain in the Abdomen, Cycle 1 Day 8, Severity, 0=None00
Pain in the Abdomen, Cycle 1 Day 8, Severity, 1=Mild42
Pain in the Abdomen, Cycle 1 Day 8, Severity, 2=Moderate45
Pain in the Abdomen, Cycle 1 Day 8, Severity, 3=Severe12
Pain in the Abdomen, Cycle 1 Day 8, Severity, 4=Very severe10
Pain in the Abdomen, Cycle 1 Day 8, Frequency, 0=Never16
Pain in the Abdomen, Cycle 1 Day 8, Frequency, 1=Rarely31
Pain in the Abdomen, Cycle 1 Day 8, Frequency, 2=Occasionally35
Pain in the Abdomen, Cycle 1 Day 8, Frequency, 3=Frequently32
Pain in the Abdomen, Cycle 1 Day 8, Frequency, 4=Almost constantly11
Pain in the Abdomen, Cycle 1 Day 15, Severity, 0=None00
Pain in the Abdomen, Cycle 1 Day 15, Severity, 1=Mild84
Pain in the Abdomen, Cycle 1 Day 15, Severity, 2=Moderate24
Pain in the Abdomen, Cycle 1 Day 15, Severity, 3=Severe11
Pain in the Abdomen, Cycle 1 Day 15, Severity, 4=Very severe00
Pain in the Abdomen, Cycle 1 Day 15, Frequency, 0=Never34
Pain in the Abdomen, Cycle 1 Day 15, Frequency, 1=Rarely62
Pain in the Abdomen, Cycle 1 Day 15, Frequency, 2=Occasionally45
Pain in the Abdomen, Cycle 1 Day 15, Frequency, 3=Frequently11
Pain in the Abdomen, Cycle 1 Day 15, Frequency, 4=Almost constantly01
Pain in the Abdomen, Cycle 2 Day 1, Severity, 0=None00
Pain in the Abdomen, Cycle 2 Day 1, Severity, 1=Mild41
Pain in the Abdomen, Cycle 2 Day 1, Severity, 2=Moderate33
Pain in the Abdomen, Cycle 2 Day 1, Severity, 3=Severe01
Pain in the Abdomen, Cycle 2 Day 1, Severity, 4=Very severe00
Pain in the Abdomen, Cycle 2 Day 1, Frequency, 0=Never49
Pain in the Abdomen, Cycle 2 Day 1, Frequency, 1=Rarely41
Pain in the Abdomen, Cycle 2 Day 1, Frequency, 2=Occasionally34
Pain in the Abdomen, Cycle 2 Day 1, Frequency, 3=Frequently00
Pain in the Abdomen, Cycle 2 Day 1, Frequency, 4=Almost constantly00
Pain in the Abdomen, Cycle 2 Day 8, Severity, 0=None10
Pain in the Abdomen, Cycle 2 Day 8, Severity, 1=Mild22
Pain in the Abdomen, Cycle 2 Day 8, Severity, 2=Moderate33
Pain in the Abdomen, Cycle 2 Day 8, Severity, 3=Severe10
Pain in the Abdomen, Cycle 2 Day 8, Severity, 4=Very severe00
Pain in the Abdomen, Cycle 2 Day 8, Frequency, 0=Never46
Pain in the Abdomen, Cycle 2 Day 8, Frequency, 1=Rarely12
Pain in the Abdomen, Cycle 2 Day 8, Frequency, 2=Occasionally43
Pain in the Abdomen, Cycle 2 Day 8, Frequency, 3=Frequently10
Pain in the Abdomen, Cycle 2 Day 8, Frequency, 4=Almost constantly10
Pain in the Abdomen, Cycle 2 Day 15, Severity, 0=None00
Pain in the Abdomen, Cycle 2 Day 15, Severity, 1=Mild75
Pain in the Abdomen, Cycle 2 Day 15, Severity, 2=Moderate03
Pain in the Abdomen, Cycle 2 Day 15, Severity, 3=Severe01
Pain in the Abdomen, Cycle 2 Day 15, Severity, 4=Very severe00
Pain in the Abdomen, Cycle 2 Day 15, Frequency, 0=Never65
Pain in the Abdomen, Cycle 2 Day 15, Frequency, 1=Rarely15
Pain in the Abdomen, Cycle 2 Day 15, Frequency, 2=Occasionally63
Pain in the Abdomen, Cycle 2 Day 15, Frequency, 3=Frequently01
Pain in the Abdomen, Cycle 2 Day 15, Frequency, 4=Almost constantly00
Pain in the Abdomen, Cycle 3 Day 1, Severity, 0=None10
Pain in the Abdomen, Cycle 3 Day 1, Severity, 1=Mild46
Pain in the Abdomen, Cycle 3 Day 1, Severity, 2=Moderate21
Pain in the Abdomen, Cycle 3 Day 1, Severity, 3=Severe11
Pain in the Abdomen, Cycle 3 Day 1, Severity, 4=Very severe00
Pain in the Abdomen, Cycle 3 Day 1, Frequency, 0=Never66
Pain in the Abdomen, Cycle 3 Day 1, Frequency, 1=Rarely33
Pain in the Abdomen, Cycle 3 Day 1, Frequency, 2=Occasionally34
Pain in the Abdomen, Cycle 3 Day 1, Frequency, 3=Frequently11
Pain in the Abdomen, Cycle 3 Day 1, Frequency, 4=Almost constantly10
Pain in the Abdomen, Cycle 3 Day 8, Severity, 0=None00
Pain in the Abdomen, Cycle 3 Day 8, Severity, 1=Mild43
Pain in the Abdomen, Cycle 3 Day 8, Severity, 2=Moderate23
Pain in the Abdomen, Cycle 3 Day 8, Severity, 3=Severe21
Pain in the Abdomen, Cycle 3 Day 8, Severity, 4=Very severe00
Pain in the Abdomen, Cycle 3 Day 8, Frequency, 0=Never23
Pain in the Abdomen, Cycle 3 Day 8, Frequency, 1=Rarely33
Pain in the Abdomen, Cycle 3 Day 8, Frequency, 2=Occasionally22
Pain in the Abdomen, Cycle 3 Day 8, Frequency, 3=Frequently32
Pain in the Abdomen, Cycle 3 Day 8, Frequency, 4=Almost constantly00
Pain in the Abdomen, Cycle 3 Day 15, Severity, 0=None20
Pain in the Abdomen, Cycle 3 Day 15, Severity, 1=Mild23
Pain in the Abdomen, Cycle 3 Day 15, Severity, 2=Moderate11
Pain in the Abdomen, Cycle 3 Day 15, Severity, 3=Severe00
Pain in the Abdomen, Cycle 3 Day 15, Severity, 4=Very severe00
Pain in the Abdomen, Cycle 3 Day 15, Frequency, 0=Never03
Pain in the Abdomen, Cycle 3 Day 15, Frequency, 1=Rarely21
Pain in the Abdomen, Cycle 3 Day 15, Frequency, 2=Occasionally32
Pain in the Abdomen, Cycle 3 Day 15, Frequency, 3=Frequently01
Pain in the Abdomen, Cycle 3 Day 15, Frequency, 4=Almost constantly00
Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 0=Never21
Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 1=Rarely00
Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 2=Occasionally00
Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 3=Frequently00
Pain in the Abdomen, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Pain in the Abdomen, End Of Treatment, Severity, 0=None—0
Pain in the Abdomen, End Of Treatment, Severity, 1=Mild—1
Pain in the Abdomen, End Of Treatment, Severity, 2=Moderate—1
Pain in the Abdomen, End Of Treatment, Severity, 3=Severe—0
Pain in the Abdomen, End Of Treatment, Severity, 4=Very severe—0
Pain in the Abdomen, End Of Treatment, Frequency, 0=Never—3
Pain in the Abdomen, End Of Treatment, Frequency, 1=Rarely—1
Pain in the Abdomen, End Of Treatment, Frequency, 2=Occasionally—1
Pain in the Abdomen, End Of Treatment, Frequency, 3=Frequently—0
Pain in the Abdomen, End Of Treatment, Frequency, 4=Almost constantly—0
Numb/Tingling Hands/Feet, Baseline, Severity, 0=None715
Numb/Tingling Hands/Feet, Baseline, Severity, 1=Mild42
Numb/Tingling Hands/Feet, Baseline, Severity, 2=Moderate20
Numb/Tingling Hands/Feet, Baseline, Severity, 3=Severe10
Numb/Tingling Hands/Feet, Baseline, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 0=None511
Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 1=Mild24
Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 2=Moderate20
Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 3=Severe20
Numb/Tingling Hands/Feet, Cycle 1 Day 8, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 0=None511
Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 1=Mild62
Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 2=Moderate30
Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 3=Severe00
Numb/Tingling Hands/Feet, Cycle 1 Day 15, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 0=None614
Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 1=Mild20
Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 2=Moderate30
Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 3=Severe00
Numb/Tingling Hands/Feet, Cycle 2 Day 1, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 0=None210
Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 1=Mild51
Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 2=Moderate20
Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 3=Severe20
Numb/Tingling Hands/Feet, Cycle 2 Day 8, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 0=None113
Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 1=Mild51
Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 2=Moderate50
Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 3=Severe20
Numb/Tingling Hands/Feet, Cycle 2 Day 15, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 0=None313
Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 1=Mild81
Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 2=Moderate30
Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 3=Severe00
Numb/Tingling Hands/Feet, Cycle 3 Day 1, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 0=None18
Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 1=Mild22
Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 2=Moderate50
Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 3=Severe10
Numb/Tingling Hands/Feet, Cycle 3 Day 8, Severity, 4=Very severe10
Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 0=None05
Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 1=Mild32
Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 2=Moderate10
Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 3=Severe10
Numb/Tingling Hands/Feet, Cycle 3 Day 15, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 0=None11
Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 1=Mild10
Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 2=Moderate00
Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 3=Severe00
Numb/Tingling Hands/Feet, Pre-IDS Evaluation, Severity, 4=Very severe00
Numb/Tingling Hands/Feet, End Of Treatment, Severity, 0=None—4
Numb/Tingling Hands/Feet, End Of Treatment, Severity, 1=Mild—0
Numb/Tingling Hands/Feet, End Of Treatment, Severity, 2=Moderate—1
Numb/Tingling Hands/Feet, End Of Treatment, Severity, 3=Severe—0
Numb/Tingling Hands/Feet, End Of Treatment, Severity, 4=Very severe—0
Probs w/Concentration, Baseline, Severity, 0=None47
Probs w/Concentration, Baseline, Severity, 1=Mild87
Probs w/Concentration, Baseline, Severity, 2=Moderate13
Probs w/Concentration, Baseline, Severity, 3=Severe10
Probs w/Concentration, Baseline, Severity, 4=Very severe00
Probs w/Concentration, Cycle 1 Day 8, Severity, 0=None34
Probs w/Concentration, Cycle 1 Day 8, Severity, 1=Mild210
Probs w/Concentration, Cycle 1 Day 8, Severity, 2=Moderate61
Probs w/Concentration, Cycle 1 Day 8, Severity, 3=Severe00
Probs w/Concentration, Cycle 1 Day 8, Severity, 4=Very severe00
Probs w/Concentration, Cycle 1 Day 15, Severity, 0=None77
Probs w/Concentration, Cycle 1 Day 15, Severity, 1=Mild53
Probs w/Concentration, Cycle 1 Day 15, Severity, 2=Moderate23
Probs w/Concentration, Cycle 1 Day 15, Severity, 3=Severe00
Probs w/Concentration, Cycle 1 Day 15, Severity, 4=Very severe00
Probs w/Concentration, Cycle 2 Day 1, Severity, 0=None56
Probs w/Concentration, Cycle 2 Day 1, Severity, 1=Mild46
Probs w/Concentration, Cycle 2 Day 1, Severity, 2=Moderate22
Probs w/Concentration, Cycle 2 Day 1, Severity, 3=Severe00
Probs w/Concentration, Cycle 2 Day 1, Severity, 4=Very severe00
Probs w/Concentration, Cycle 2 Day 8, Severity, 0=None37
Probs w/Concentration, Cycle 2 Day 8, Severity, 1=Mild44
Probs w/Concentration, Cycle 2 Day 8, Severity, 2=Moderate30
Probs w/Concentration, Cycle 2 Day 8, Severity, 3=Severe00
Probs w/Concentration, Cycle 2 Day 8, Severity, 4=Very severe10
Probs w/Concentration, Cycle 2 Day 15, Severity, 0=None49
Probs w/Concentration, Cycle 2 Day 15, Severity, 1=Mild84
Probs w/Concentration, Cycle 2 Day 15, Severity, 2=Moderate11
Probs w/Concentration, Cycle 2 Day 15, Severity, 3=Severe00
Probs w/Concentration, Cycle 2 Day 15, Severity, 4=Very severe00
Probs w/Concentration, Cycle 3 Day 1, Severity, 0=None89
Probs w/Concentration, Cycle 3 Day 1, Severity, 1=Mild53
Probs w/Concentration, Cycle 3 Day 1, Severity, 2=Moderate11
Probs w/Concentration, Cycle 3 Day 1, Severity, 3=Severe01
Probs w/Concentration, Cycle 3 Day 1, Severity, 4=Very severe00
Probs w/Concentration, Cycle 3 Day 8, Severity, 0=None45
Probs w/Concentration, Cycle 3 Day 8, Severity, 1=Mild14
Probs w/Concentration, Cycle 3 Day 8, Severity, 2=Moderate41
Probs w/Concentration, Cycle 3 Day 8, Severity, 3=Severe10
Probs w/Concentration, Cycle 3 Day 8, Severity, 4=Very severe00
Probs w/Concentration, Cycle 3 Day 15, Severity, 0=None14
Probs w/Concentration, Cycle 3 Day 15, Severity, 1=Mild32
Probs w/Concentration, Cycle 3 Day 15, Severity, 2=Moderate11
Probs w/Concentration, Cycle 3 Day 15, Severity, 3=Severe00
Probs w/Concentration, Cycle 3 Day 15, Severity, 4=Very severe00
Probs w/Concentration, Pre-IDS Evaluation, Severity, 0=None20
Probs w/Concentration, Pre-IDS Evaluation, Severity, 1=Mild00
Probs w/Concentration, Pre-IDS Evaluation, Severity, 2=Moderate00
Probs w/Concentration, Pre-IDS Evaluation, Severity, 3=Severe01
Probs w/Concentration, Pre-IDS Evaluation, Severity, 4=Very severe00
Probs w/Concentration, End Of Treatment, Severity, 0=None—3
Probs w/Concentration, End Of Treatment, Severity, 1=Mild—1
Probs w/Concentration, End Of Treatment, Severity, 2=Moderate—1
Probs w/Concentration, End Of Treatment, Severity, 3=Severe—0
Probs w/Concentration, End Of Treatment, Severity, 4=Very severe—0
Problems w/Memory, Baseline, Severity, 0=None76
Problems w/Memory, Baseline, Severity, 1=Mild68
Problems w/Memory, Baseline, Severity, 2=Moderate02
Problems w/Memory, Baseline, Severity, 3=Severe01
Problems w/Memory, Baseline, Severity, 4=Very severe10
Problems w/Memory, Cycle 1 Day 8, Severity, 0=None75
Problems w/Memory, Cycle 1 Day 8, Severity, 1=Mild38
Problems w/Memory, Cycle 1 Day 8, Severity, 2=Moderate12
Problems w/Memory, Cycle 1 Day 8, Severity, 3=Severe00
Problems w/Memory, Cycle 1 Day 8, Severity, 4=Very severe00
Problems w/Memory, Cycle 1 Day 15, Severity, 0=None65
Problems w/Memory, Cycle 1 Day 15, Severity, 1=Mild76
Problems w/Memory, Cycle 1 Day 15, Severity, 2=Moderate12
Problems w/Memory, Cycle 1 Day 15, Severity, 3=Severe00
Problems w/Memory, Cycle 1 Day 15, Severity, 4=Very severe00
Problems w/Memory, Cycle 2 Day 1, Severity, 0=None56
Problems w/Memory, Cycle 2 Day 1, Severity, 1=Mild45
Problems w/Memory, Cycle 2 Day 1, Severity, 2=Moderate23
Problems w/Memory, Cycle 2 Day 1, Severity, 3=Severe00
Problems w/Memory, Cycle 2 Day 1, Severity, 4=Very severe00
Problems w/Memory, Cycle 2 Day 8, Severity, 0=None56
Problems w/Memory, Cycle 2 Day 8, Severity, 1=Mild54
Problems w/Memory, Cycle 2 Day 8, Severity, 2=Moderate11
Problems w/Memory, Cycle 2 Day 8, Severity, 3=Severe00
Problems w/Memory, Cycle 2 Day 8, Severity, 4=Very severe00
Problems w/Memory, Cycle 2 Day 15, Severity, 0=None65
Problems w/Memory, Cycle 2 Day 15, Severity, 1=Mild77
Problems w/Memory, Cycle 2 Day 15, Severity, 2=Moderate01
Problems w/Memory, Cycle 2 Day 15, Severity, 3=Severe01
Problems w/Memory, Cycle 2 Day 15, Severity, 4=Very severe00
Problems w/Memory, Cycle 3 Day 1, Severity, 0=None89
Problems w/Memory, Cycle 3 Day 1, Severity, 1=Mild63
Problems w/Memory, Cycle 3 Day 1, Severity, 2=Moderate01
Problems w/Memory, Cycle 3 Day 1, Severity, 3=Severe00
Problems w/Memory, Cycle 3 Day 1, Severity, 4=Very severe01
Problems w/Memory, Cycle 3 Day 8, Severity, 0=None54
Problems w/Memory, Cycle 3 Day 8, Severity, 1=Mild15
Problems w/Memory, Cycle 3 Day 8, Severity, 2=Moderate31
Problems w/Memory, Cycle 3 Day 8, Severity, 3=Severe10
Problems w/Memory, Cycle 3 Day 8, Severity, 4=Very severe00
Problems w/Memory, Cycle 3 Day 15, Severity, 0=None24
Problems w/Memory, Cycle 3 Day 15, Severity, 1=Mild32
Problems w/Memory, Cycle 3 Day 15, Severity, 2=Moderate01
Problems w/Memory, Cycle 3 Day 15, Severity, 3=Severe00
Problems w/Memory, Cycle 3 Day 15, Severity, 4=Very severe00
Problems w/Memory, Pre-IDS Evaluation, Severity, 0=None20
Problems w/Memory, Pre-IDS Evaluation, Severity, 1=Mild00
Problems w/Memory, Pre-IDS Evaluation, Severity, 2=Moderate00
Problems w/Memory, Pre-IDS Evaluation, Severity, 3=Severe00
Problems w/Memory, Pre-IDS Evaluation, Severity, 4=Very severe01
Problems w/Memory, End Of Treatment, Severity, 0=None—4
Problems w/Memory, End Of Treatment, Severity, 1=Mild—1
Problems w/Memory, End Of Treatment, Severity, 2=Moderate—0
Problems w/Memory, End Of Treatment, Severity, 3=Severe—0
Problems w/Memory, End Of Treatment, Severity, 4=Very severe—0
Aching Muscles, Baseline, Severity, 0=None10
Aching Muscles, Baseline, Severity, 1=Mild04
Aching Muscles, Baseline, Severity, 2=Moderate14
Aching Muscles, Baseline, Severity, 3=Severe12
Aching Muscles, Baseline, Severity, 4=Very severe00
Aching Muscles, Baseline, Frequency, 0=Never117
Aching Muscles, Baseline, Frequency, 1=Rarely16
Aching Muscles, Baseline, Frequency, 2=Occasionally12
Aching Muscles, Baseline, Frequency, 3=Frequently02
Aching Muscles, Baseline, Frequency, 4=Almost constantly10
Aching Muscles, Cycle 1 Day 8, Severity, 0=None10
Aching Muscles, Cycle 1 Day 8, Severity, 1=Mild14
Aching Muscles, Cycle 1 Day 8, Severity, 2=Moderate23
Aching Muscles, Cycle 1 Day 8, Severity, 3=Severe10
Aching Muscles, Cycle 1 Day 8, Severity, 4=Very severe40
Aching Muscles, Cycle 1 Day 8, Frequency, 0=Never28
Aching Muscles, Cycle 1 Day 8, Frequency, 1=Rarely23
Aching Muscles, Cycle 1 Day 8, Frequency, 2=Occasionally22
Aching Muscles, Cycle 1 Day 8, Frequency, 3=Frequently12
Aching Muscles, Cycle 1 Day 8, Frequency, 4=Almost constantly40
Aching Muscles, Cycle 1 Day 15, Severity, 0=None10
Aching Muscles, Cycle 1 Day 15, Severity, 1=Mild51
Aching Muscles, Cycle 1 Day 15, Severity, 2=Moderate23
Aching Muscles, Cycle 1 Day 15, Severity, 3=Severe01
Aching Muscles, Cycle 1 Day 15, Severity, 4=Very severe10
Aching Muscles, Cycle 1 Day 15, Frequency, 0=Never58
Aching Muscles, Cycle 1 Day 15, Frequency, 1=Rarely31
Aching Muscles, Cycle 1 Day 15, Frequency, 2=Occasionally54
Aching Muscles, Cycle 1 Day 15, Frequency, 3=Frequently00
Aching Muscles, Cycle 1 Day 15, Frequency, 4=Almost constantly10
Aching Muscles, Cycle 2 Day 1, Severity, 0=None00
Aching Muscles, Cycle 2 Day 1, Severity, 1=Mild32
Aching Muscles, Cycle 2 Day 1, Severity, 2=Moderate04
Aching Muscles, Cycle 2 Day 1, Severity, 3=Severe00
Aching Muscles, Cycle 2 Day 1, Severity, 4=Very severe00
Aching Muscles, Cycle 2 Day 1, Frequency, 0=Never88
Aching Muscles, Cycle 2 Day 1, Frequency, 1=Rarely11
Aching Muscles, Cycle 2 Day 1, Frequency, 2=Occasionally23
Aching Muscles, Cycle 2 Day 1, Frequency, 3=Frequently02
Aching Muscles, Cycle 2 Day 1, Frequency, 4=Almost constantly00
Aching Muscles, Cycle 2 Day 8, Severity, 0=None00
Aching Muscles, Cycle 2 Day 8, Severity, 1=Mild32
Aching Muscles, Cycle 2 Day 8, Severity, 2=Moderate42
Aching Muscles, Cycle 2 Day 8, Severity, 3=Severe21
Aching Muscles, Cycle 2 Day 8, Severity, 4=Very severe10
Aching Muscles, Cycle 2 Day 8, Frequency, 0=Never16
Aching Muscles, Cycle 2 Day 8, Frequency, 1=Rarely42
Aching Muscles, Cycle 2 Day 8, Frequency, 2=Occasionally12
Aching Muscles, Cycle 2 Day 8, Frequency, 3=Frequently41
Aching Muscles, Cycle 2 Day 8, Frequency, 4=Almost constantly10
Aching Muscles, Cycle 2 Day 15, Severity, 0=None00
Aching Muscles, Cycle 2 Day 15, Severity, 1=Mild56
Aching Muscles, Cycle 2 Day 15, Severity, 2=Moderate10
Aching Muscles, Cycle 2 Day 15, Severity, 3=Severe21
Aching Muscles, Cycle 2 Day 15, Severity, 4=Very severe10
Aching Muscles, Cycle 2 Day 15, Frequency, 0=Never47
Aching Muscles, Cycle 2 Day 15, Frequency, 1=Rarely35
Aching Muscles, Cycle 2 Day 15, Frequency, 2=Occasionally41
Aching Muscles, Cycle 2 Day 15, Frequency, 3=Frequently11
Aching Muscles, Cycle 2 Day 15, Frequency, 4=Almost constantly10
Aching Muscles, Cycle 3 Day 1, Severity, 0=None10
Aching Muscles, Cycle 3 Day 1, Severity, 1=Mild56
Aching Muscles, Cycle 3 Day 1, Severity, 2=Moderate11
Aching Muscles, Cycle 3 Day 1, Severity, 3=Severe11
Aching Muscles, Cycle 3 Day 1, Severity, 4=Very severe10
Aching Muscles, Cycle 3 Day 1, Frequency, 0=Never56
Aching Muscles, Cycle 3 Day 1, Frequency, 1=Rarely55
Aching Muscles, Cycle 3 Day 1, Frequency, 2=Occasionally21
Aching Muscles, Cycle 3 Day 1, Frequency, 3=Frequently11
Aching Muscles, Cycle 3 Day 1, Frequency, 4=Almost constantly11
Aching Muscles, Cycle 3 Day 8, Severity, 0=None00
Aching Muscles, Cycle 3 Day 8, Severity, 1=Mild12
Aching Muscles, Cycle 3 Day 8, Severity, 2=Moderate22
Aching Muscles, Cycle 3 Day 8, Severity, 3=Severe31
Aching Muscles, Cycle 3 Day 8, Severity, 4=Very severe00
Aching Muscles, Cycle 3 Day 8, Frequency, 0=Never45
Aching Muscles, Cycle 3 Day 8, Frequency, 1=Rarely12
Aching Muscles, Cycle 3 Day 8, Frequency, 2=Occasionally22
Aching Muscles, Cycle 3 Day 8, Frequency, 3=Frequently31
Aching Muscles, Cycle 3 Day 8, Frequency, 4=Almost constantly00
Aching Muscles, Cycle 3 Day 15, Severity, 0=None10
Aching Muscles, Cycle 3 Day 15, Severity, 1=Mild13
Aching Muscles, Cycle 3 Day 15, Severity, 2=Moderate10
Aching Muscles, Cycle 3 Day 15, Severity, 3=Severe00
Aching Muscles, Cycle 3 Day 15, Severity, 4=Very severe00
Aching Muscles, Cycle 3 Day 15, Frequency, 0=Never24
Aching Muscles, Cycle 3 Day 15, Frequency, 1=Rarely12
Aching Muscles, Cycle 3 Day 15, Frequency, 2=Occasionally11
Aching Muscles, Cycle 3 Day 15, Frequency, 3=Frequently10
Aching Muscles, Cycle 3 Day 15, Frequency, 4=Almost constantly00
Aching Muscles, Pre-IDS Evaluation, Severity, 0=None0—
Aching Muscles, Pre-IDS Evaluation, Severity, 1=Mild1—
Aching Muscles, Pre-IDS Evaluation, Severity, 2=Moderate0—
Aching Muscles, Pre-IDS Evaluation, Severity, 3=Severe0—
Aching Muscles, Pre-IDS Evaluation, Severity, 4=Very severe0—
Aching Muscles, Pre-IDS Evaluation, Frequency, 0=Never11
Aching Muscles, Pre-IDS Evaluation, Frequency, 1=Rarely10
Aching Muscles, Pre-IDS Evaluation, Frequency, 2=Occasionally00
Aching Muscles, Pre-IDS Evaluation, Frequency, 3=Frequently00
Aching Muscles, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Aching Muscles, End Of Treatment, Severity, 0=None—0
Aching Muscles, End Of Treatment, Severity, 1=Mild—4
Aching Muscles, End Of Treatment, Severity, 2=Moderate—0
Aching Muscles, End Of Treatment, Severity, 3=Severe—0
Aching Muscles, End Of Treatment, Severity, 4=Very severe—0
Aching Muscles, End Of Treatment, Frequency, 0=Never—1
Aching Muscles, End Of Treatment, Frequency, 1=Rarely—4
Aching Muscles, End Of Treatment, Frequency, 2=Occasionally—0
Aching Muscles, End Of Treatment, Frequency, 3=Frequently—0
Aching Muscles, End Of Treatment, Frequency, 4=Almost constantly—0
Aching Joints, Baseline, Severity, 0=None00
Aching Joints, Baseline, Severity, 1=Mild33
Aching Joints, Baseline, Severity, 2=Moderate11
Aching Joints, Baseline, Severity, 3=Severe12
Aching Joints, Baseline, Severity, 4=Very severe00
Aching Joints, Baseline, Frequency, 0=Never911
Aching Joints, Baseline, Frequency, 1=Rarely33
Aching Joints, Baseline, Frequency, 2=Occasionally11
Aching Joints, Baseline, Frequency, 3=Frequently11
Aching Joints, Baseline, Frequency, 4=Almost constantly01
Aching Joints, Cycle 1 Day 8, Severity, 0=None00
Aching Joints, Cycle 1 Day 8, Severity, 1=Mild31
Aching Joints, Cycle 1 Day 8, Severity, 2=Moderate11
Aching Joints, Cycle 1 Day 8, Severity, 3=Severe31
Aching Joints, Cycle 1 Day 8, Severity, 4=Very severe10
Aching Joints, Cycle 1 Day 8, Frequency, 0=Never312
Aching Joints, Cycle 1 Day 8, Frequency, 1=Rarely40
Aching Joints, Cycle 1 Day 8, Frequency, 2=Occasionally02
Aching Joints, Cycle 1 Day 8, Frequency, 3=Frequently20
Aching Joints, Cycle 1 Day 8, Frequency, 4=Almost constantly21
Aching Joints, Cycle 1 Day 15, Severity, 0=None00
Aching Joints, Cycle 1 Day 15, Severity, 1=Mild43
Aching Joints, Cycle 1 Day 15, Severity, 2=Moderate22
Aching Joints, Cycle 1 Day 15, Severity, 3=Severe00
Aching Joints, Cycle 1 Day 15, Severity, 4=Very severe10
Aching Joints, Cycle 1 Day 15, Frequency, 0=Never78
Aching Joints, Cycle 1 Day 15, Frequency, 1=Rarely43
Aching Joints, Cycle 1 Day 15, Frequency, 2=Occasionally22
Aching Joints, Cycle 1 Day 15, Frequency, 3=Frequently00
Aching Joints, Cycle 1 Day 15, Frequency, 4=Almost constantly10
Aching Joints, Cycle 2 Day 1, Severity, 0=None11
Aching Joints, Cycle 2 Day 1, Severity, 1=Mild41
Aching Joints, Cycle 2 Day 1, Severity, 2=Moderate13
Aching Joints, Cycle 2 Day 1, Severity, 3=Severe01
Aching Joints, Cycle 2 Day 1, Severity, 4=Very severe00
Aching Joints, Cycle 2 Day 1, Frequency, 0=Never58
Aching Joints, Cycle 2 Day 1, Frequency, 1=Rarely42
Aching Joints, Cycle 2 Day 1, Frequency, 2=Occasionally13
Aching Joints, Cycle 2 Day 1, Frequency, 3=Frequently11
Aching Joints, Cycle 2 Day 1, Frequency, 4=Almost constantly00
Aching Joints, Cycle 2 Day 8, Severity, 0=None10
Aching Joints, Cycle 2 Day 8, Severity, 1=Mild23
Aching Joints, Cycle 2 Day 8, Severity, 2=Moderate40
Aching Joints, Cycle 2 Day 8, Severity, 3=Severe21
Aching Joints, Cycle 2 Day 8, Severity, 4=Very severe10
Aching Joints, Cycle 2 Day 8, Frequency, 0=Never17
Aching Joints, Cycle 2 Day 8, Frequency, 1=Rarely32
Aching Joints, Cycle 2 Day 8, Frequency, 2=Occasionally41
Aching Joints, Cycle 2 Day 8, Frequency, 3=Frequently21
Aching Joints, Cycle 2 Day 8, Frequency, 4=Almost constantly10
Aching Joints, Cycle 2 Day 15, Severity, 0=None20
Aching Joints, Cycle 2 Day 15, Severity, 1=Mild53
Aching Joints, Cycle 2 Day 15, Severity, 2=Moderate21
Aching Joints, Cycle 2 Day 15, Severity, 3=Severe01
Aching Joints, Cycle 2 Day 15, Severity, 4=Very severe10
Aching Joints, Cycle 2 Day 15, Frequency, 0=Never39
Aching Joints, Cycle 2 Day 15, Frequency, 1=Rarely53
Aching Joints, Cycle 2 Day 15, Frequency, 2=Occasionally31
Aching Joints, Cycle 2 Day 15, Frequency, 3=Frequently11
Aching Joints, Cycle 2 Day 15, Frequency, 4=Almost constantly10
Aching Joints, Cycle 3 Day 1, Severity, 0=None01
Aching Joints, Cycle 3 Day 1, Severity, 1=Mild33
Aching Joints, Cycle 3 Day 1, Severity, 2=Moderate41
Aching Joints, Cycle 3 Day 1, Severity, 3=Severe11
Aching Joints, Cycle 3 Day 1, Severity, 4=Very severe00
Aching Joints, Cycle 3 Day 1, Frequency, 0=Never68
Aching Joints, Cycle 3 Day 1, Frequency, 1=Rarely34
Aching Joints, Cycle 3 Day 1, Frequency, 2=Occasionally30
Aching Joints, Cycle 3 Day 1, Frequency, 3=Frequently21
Aching Joints, Cycle 3 Day 1, Frequency, 4=Almost constantly01
Aching Joints, Cycle 3 Day 8, Severity, 0=None10
Aching Joints, Cycle 3 Day 8, Severity, 1=Mild04
Aching Joints, Cycle 3 Day 8, Severity, 2=Moderate20
Aching Joints, Cycle 3 Day 8, Severity, 3=Severe31
Aching Joints, Cycle 3 Day 8, Severity, 4=Very severe00
Aching Joints, Cycle 3 Day 8, Frequency, 0=Never45
Aching Joints, Cycle 3 Day 8, Frequency, 1=Rarely13
Aching Joints, Cycle 3 Day 8, Frequency, 2=Occasionally01
Aching Joints, Cycle 3 Day 8, Frequency, 3=Frequently41
Aching Joints, Cycle 3 Day 8, Frequency, 4=Almost constantly10
Aching Joints, Cycle 3 Day 15, Severity, 0=None10
Aching Joints, Cycle 3 Day 15, Severity, 1=Mild12
Aching Joints, Cycle 3 Day 15, Severity, 2=Moderate10
Aching Joints, Cycle 3 Day 15, Severity, 3=Severe10
Aching Joints, Cycle 3 Day 15, Severity, 4=Very severe00
Aching Joints, Cycle 3 Day 15, Frequency, 0=Never15
Aching Joints, Cycle 3 Day 15, Frequency, 1=Rarely21
Aching Joints, Cycle 3 Day 15, Frequency, 2=Occasionally11
Aching Joints, Cycle 3 Day 15, Frequency, 3=Frequently00
Aching Joints, Cycle 3 Day 15, Frequency, 4=Almost constantly10
Aching Joints, Pre-IDS Evaluation, Frequency, 0=Never21
Aching Joints, Pre-IDS Evaluation, Frequency, 1=Rarely00
Aching Joints, Pre-IDS Evaluation, Frequency, 2=Occasionally00
Aching Joints, Pre-IDS Evaluation, Frequency, 3=Frequently00
Aching Joints, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Aching Joints, End Of Treatment, Severity, 0=None—1
Aching Joints, End Of Treatment, Severity, 1=Mild—1
Aching Joints, End Of Treatment, Severity, 2=Moderate—0
Aching Joints, End Of Treatment, Severity, 3=Severe—0
Aching Joints, End Of Treatment, Severity, 4=Very severe—0
Aching Joints, End Of Treatment, Frequency, 0=Never—3
Aching Joints, End Of Treatment, Frequency, 1=Rarely—2
Aching Joints, End Of Treatment, Frequency, 2=Occasionally—0
Aching Joints, End Of Treatment, Frequency, 3=Frequently—0
Aching Joints, End Of Treatment, Frequency, 4=Almost constantly—0
Fatigue/Lack of Energy, Baseline, Severity, 0=None33
Fatigue/Lack of Energy, Baseline, Severity, 1=Mild25
Fatigue/Lack of Energy, Baseline, Severity, 2=Moderate86
Fatigue/Lack of Energy, Baseline, Severity, 3=Severe13
Fatigue/Lack of Energy, Baseline, Severity, 4=Very severe00
Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 0=None00
Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 1=Mild17
Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 2=Moderate32
Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 3=Severe76
Fatigue/Lack of Energy, Cycle 1 Day 8, Severity, 4=Very severe00
Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 0=None22
Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 1=Mild53
Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 2=Moderate54
Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 3=Severe14
Fatigue/Lack of Energy, Cycle 1 Day 15, Severity, 4=Very severe10
Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 0=None31
Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 1=Mild46
Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 2=Moderate45
Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 3=Severe02
Fatigue/Lack of Energy, Cycle 2 Day 1, Severity, 4=Very severe00
Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 0=None01
Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 1=Mild46
Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 2=Moderate33
Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 3=Severe21
Fatigue/Lack of Energy, Cycle 2 Day 8, Severity, 4=Very severe20
Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 0=None22
Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 1=Mild25
Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 2=Moderate76
Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 3=Severe21
Fatigue/Lack of Energy, Cycle 2 Day 15, Severity, 4=Very severe00
Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 0=None22
Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 1=Mild76
Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 2=Moderate54
Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 3=Severe02
Fatigue/Lack of Energy, Cycle 3 Day 1, Severity, 4=Very severe00
Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 0=None01
Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 1=Mild23
Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 2=Moderate35
Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 3=Severe31
Fatigue/Lack of Energy, Cycle 3 Day 8, Severity, 4=Very severe20
Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 0=None00
Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 1=Mild43
Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 2=Moderate14
Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 3=Severe00
Fatigue/Lack of Energy, Cycle 3 Day 15, Severity, 4=Very severe00
Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 0=None10
Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 1=Mild10
Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 2=Moderate01
Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 3=Severe00
Fatigue/Lack of Energy, Pre-IDS Evaluation, Severity, 4=Very severe00
Fatigue/Lack of Energy, End Of Treatment, Severity, 0=None—2
Fatigue/Lack of Energy, End Of Treatment, Severity, 1=Mild—2
Fatigue/Lack of Energy, End Of Treatment, Severity, 2=Moderate—1
Fatigue/Lack of Energy, End Of Treatment, Severity, 3=Severe—0
Fatigue/Lack of Energy, End Of Treatment, Severity, 4=Very severe—0
Anxiety, Baseline, Severity, 0=None11
Anxiety, Baseline, Severity, 1=Mild56
Anxiety, Baseline, Severity, 2=Moderate43
Anxiety, Baseline, Severity, 3=Severe01
Anxiety, Baseline, Severity, 4=Very severe01
Anxiety, Baseline, Frequency, 0=Never45
Anxiety, Baseline, Frequency, 1=Rarely46
Anxiety, Baseline, Frequency, 2=Occasionally54
Anxiety, Baseline, Frequency, 3=Frequently00
Anxiety, Baseline, Frequency, 4=Almost constantly12
Anxiety, Cycle 1 Day 8, Severity, 0=None20
Anxiety, Cycle 1 Day 8, Severity, 1=Mild43
Anxiety, Cycle 1 Day 8, Severity, 2=Moderate13
Anxiety, Cycle 1 Day 8, Severity, 3=Severe12
Anxiety, Cycle 1 Day 8, Severity, 4=Very severe00
Anxiety, Cycle 1 Day 8, Frequency, 0=Never37
Anxiety, Cycle 1 Day 8, Frequency, 1=Rarely63
Anxiety, Cycle 1 Day 8, Frequency, 2=Occasionally12
Anxiety, Cycle 1 Day 8, Frequency, 3=Frequently12
Anxiety, Cycle 1 Day 8, Frequency, 4=Almost constantly01
Anxiety, Cycle 1 Day 15, Severity, 0=None10
Anxiety, Cycle 1 Day 15, Severity, 1=Mild43
Anxiety, Cycle 1 Day 15, Severity, 2=Moderate22
Anxiety, Cycle 1 Day 15, Severity, 3=Severe02
Anxiety, Cycle 1 Day 15, Severity, 4=Very severe00
Anxiety, Cycle 1 Day 15, Frequency, 0=Never76
Anxiety, Cycle 1 Day 15, Frequency, 1=Rarely63
Anxiety, Cycle 1 Day 15, Frequency, 2=Occasionally03
Anxiety, Cycle 1 Day 15, Frequency, 3=Frequently11
Anxiety, Cycle 1 Day 15, Frequency, 4=Almost constantly00
Anxiety, Cycle 2 Day 1, Severity, 0=None01
Anxiety, Cycle 2 Day 1, Severity, 1=Mild46
Anxiety, Cycle 2 Day 1, Severity, 2=Moderate20
Anxiety, Cycle 2 Day 1, Severity, 3=Severe01
Anxiety, Cycle 2 Day 1, Severity, 4=Very severe00
Anxiety, Cycle 2 Day 1, Frequency, 0=Never56
Anxiety, Cycle 2 Day 1, Frequency, 1=Rarely46
Anxiety, Cycle 2 Day 1, Frequency, 2=Occasionally22
Anxiety, Cycle 2 Day 1, Frequency, 3=Frequently00
Anxiety, Cycle 2 Day 1, Frequency, 4=Almost constantly00
Anxiety, Cycle 2 Day 8, Severity, 0=None10
Anxiety, Cycle 2 Day 8, Severity, 1=Mild23
Anxiety, Cycle 2 Day 8, Severity, 2=Moderate31
Anxiety, Cycle 2 Day 8, Severity, 3=Severe10
Anxiety, Cycle 2 Day 8, Severity, 4=Very severe00
Anxiety, Cycle 2 Day 8, Frequency, 0=Never47
Anxiety, Cycle 2 Day 8, Frequency, 1=Rarely23
Anxiety, Cycle 2 Day 8, Frequency, 2=Occasionally41
Anxiety, Cycle 2 Day 8, Frequency, 3=Frequently10
Anxiety, Cycle 2 Day 8, Frequency, 4=Almost constantly00
Anxiety, Cycle 2 Day 15, Severity, 0=None00
Anxiety, Cycle 2 Day 15, Severity, 1=Mild43
Anxiety, Cycle 2 Day 15, Severity, 2=Moderate42
Anxiety, Cycle 2 Day 15, Severity, 3=Severe01
Anxiety, Cycle 2 Day 15, Severity, 4=Very severe00
Anxiety, Cycle 2 Day 15, Frequency, 0=Never58
Anxiety, Cycle 2 Day 15, Frequency, 1=Rarely22
Anxiety, Cycle 2 Day 15, Frequency, 2=Occasionally61
Anxiety, Cycle 2 Day 15, Frequency, 3=Frequently02
Anxiety, Cycle 2 Day 15, Frequency, 4=Almost constantly01
Anxiety, Cycle 3 Day 1, Severity, 0=None10
Anxiety, Cycle 3 Day 1, Severity, 1=Mild75
Anxiety, Cycle 3 Day 1, Severity, 2=Moderate13
Anxiety, Cycle 3 Day 1, Severity, 3=Severe00
Anxiety, Cycle 3 Day 1, Severity, 4=Very severe00
Anxiety, Cycle 3 Day 1, Frequency, 0=Never56
Anxiety, Cycle 3 Day 1, Frequency, 1=Rarely55
Anxiety, Cycle 3 Day 1, Frequency, 2=Occasionally42
Anxiety, Cycle 3 Day 1, Frequency, 3=Frequently01
Anxiety, Cycle 3 Day 1, Frequency, 4=Almost constantly00
Anxiety, Cycle 3 Day 8, Severity, 0=None10
Anxiety, Cycle 3 Day 8, Severity, 1=Mild13
Anxiety, Cycle 3 Day 8, Severity, 2=Moderate33
Anxiety, Cycle 3 Day 8, Severity, 3=Severe00
Anxiety, Cycle 3 Day 8, Severity, 4=Very severe00
Anxiety, Cycle 3 Day 8, Frequency, 0=Never54
Anxiety, Cycle 3 Day 8, Frequency, 1=Rarely13
Anxiety, Cycle 3 Day 8, Frequency, 2=Occasionally22
Anxiety, Cycle 3 Day 8, Frequency, 3=Frequently21
Anxiety, Cycle 3 Day 8, Frequency, 4=Almost constantly00
Anxiety, Cycle 3 Day 15, Severity, 0=None10
Anxiety, Cycle 3 Day 15, Severity, 1=Mild14
Anxiety, Cycle 3 Day 15, Severity, 2=Moderate20
Anxiety, Cycle 3 Day 15, Severity, 3=Severe00
Anxiety, Cycle 3 Day 15, Severity, 4=Very severe00
Anxiety, Cycle 3 Day 15, Frequency, 0=Never13
Anxiety, Cycle 3 Day 15, Frequency, 1=Rarely23
Anxiety, Cycle 3 Day 15, Frequency, 2=Occasionally21
Anxiety, Cycle 3 Day 15, Frequency, 3=Frequently00
Anxiety, Cycle 3 Day 15, Frequency, 4=Almost constantly00
Anxiety, Pre-IDS Evaluation, Severity, 0=None—0
Anxiety, Pre-IDS Evaluation, Severity, 1=Mild—1
Anxiety, Pre-IDS Evaluation, Severity, 2=Moderate—0
Anxiety, Pre-IDS Evaluation, Severity, 3=Severe—0
Anxiety, Pre-IDS Evaluation, Severity, 4=Very severe—0
Anxiety, Pre-IDS Evaluation, Frequency, 0=Never20
Anxiety, Pre-IDS Evaluation, Frequency, 1=Rarely01
Anxiety, Pre-IDS Evaluation, Frequency, 2=Occasionally00
Anxiety, Pre-IDS Evaluation, Frequency, 3=Frequently00
Anxiety, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Anxiety, End Of Treatment, Severity, 0=None—1
Anxiety, End Of Treatment, Severity, 1=Mild—2
Anxiety, End Of Treatment, Severity, 2=Moderate—1
Anxiety, End Of Treatment, Severity, 3=Severe—0
Anxiety, End Of Treatment, Severity, 4=Very severe—0
Anxiety, End Of Treatment, Frequency, 0=Never—1
Anxiety, End Of Treatment, Frequency, 1=Rarely—2
Anxiety, End Of Treatment, Frequency, 2=Occasionally—2
Anxiety, End Of Treatment, Frequency, 3=Frequently—0
Anxiety, End Of Treatment, Frequency, 4=Almost constantly—0
Sad or Unhappy Feelings, Baseline, Severity, 0=None12
Sad or Unhappy Feelings, Baseline, Severity, 1=Mild85
Sad or Unhappy Feelings, Baseline, Severity, 2=Moderate34
Sad or Unhappy Feelings, Baseline, Severity, 3=Severe01
Sad or Unhappy Feelings, Baseline, Severity, 4=Very severe01
Sad or Unhappy Feelings, Baseline, Frequency, 0=Never24
Sad or Unhappy Feelings, Baseline, Frequency, 1=Rarely46
Sad or Unhappy Feelings, Baseline, Frequency, 2=Occasionally85
Sad or Unhappy Feelings, Baseline, Frequency, 3=Frequently01
Sad or Unhappy Feelings, Baseline, Frequency, 4=Almost constantly01
Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 0=None11
Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 1=Mild65
Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 2=Moderate22
Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 3=Severe12
Sad or Unhappy Feelings, Cycle 1 Day 8, Severity, 4=Very severe00
Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 0=Never15
Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 1=Rarely56
Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 2=Occasionally43
Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 3=Frequently10
Sad or Unhappy Feelings, Cycle 1 Day 8, Frequency, 4=Almost constantly01
Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 0=None10
Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 1=Mild55
Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 2=Moderate22
Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 3=Severe02
Sad or Unhappy Feelings, Cycle 1 Day 15, Severity, 4=Very severe00
Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 0=Never64
Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 1=Rarely55
Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 2=Occasionally23
Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 3=Frequently11
Sad or Unhappy Feelings, Cycle 1 Day 15, Frequency, 4=Almost constantly00
Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 0=None01
Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 1=Mild37
Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 2=Moderate21
Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 3=Severe00
Sad or Unhappy Feelings, Cycle 2 Day 1, Severity, 4=Very severe00
Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 0=Never65
Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 1=Rarely18
Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 2=Occasionally41
Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 3=Frequently00
Sad or Unhappy Feelings, Cycle 2 Day 1, Frequency, 4=Almost constantly00
Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 0=None12
Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 1=Mild36
Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 2=Moderate20
Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 3=Severe00
Sad or Unhappy Feelings, Cycle 2 Day 8, Severity, 4=Very severe10
Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 0=Never43
Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 1=Rarely38
Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 2=Occasionally20
Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 3=Frequently10
Sad or Unhappy Feelings, Cycle 2 Day 8, Frequency, 4=Almost constantly10
Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 0=None03
Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 1=Mild56
Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 2=Moderate42
Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 3=Severe00
Sad or Unhappy Feelings, Cycle 2 Day 15, Severity, 4=Very severe00
Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 0=Never43
Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 1=Rarely47
Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 2=Occasionally43
Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 3=Frequently11
Sad or Unhappy Feelings, Cycle 2 Day 15, Frequency, 4=Almost constantly00
Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 0=None11
Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 1=Mild68
Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 2=Moderate11
Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 3=Severe00
Sad or Unhappy Feelings, Cycle 3 Day 1, Severity, 4=Very severe00
Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 0=Never64
Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 1=Rarely69
Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 2=Occasionally11
Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 3=Frequently10
Sad or Unhappy Feelings, Cycle 3 Day 1, Frequency, 4=Almost constantly00
Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 0=None21
Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 1=Mild04
Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 2=Moderate22
Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 3=Severe10
Sad or Unhappy Feelings, Cycle 3 Day 8, Severity, 4=Very severe00
Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 0=Never53
Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 1=Rarely25
Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 2=Occasionally21
Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 3=Frequently11
Sad or Unhappy Feelings, Cycle 3 Day 8, Frequency, 4=Almost constantly00
Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 0=None10
Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 1=Mild44
Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 2=Moderate00
Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 3=Severe00
Sad or Unhappy Feelings, Cycle 3 Day 15, Severity, 4=Very severe00
Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 0=Never03
Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 1=Rarely43
Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 2=Occasionally11
Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 3=Frequently00
Sad or Unhappy Feelings, Cycle 3 Day 15, Frequency, 4=Almost constantly00
Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 0=None—0
Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 1=Mild—1
Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 2=Moderate—0
Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 3=Severe—0
Sad or Unhappy Feelings, Pre-IDS Evaluation, Severity, 4=Very severe—0
Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 0=Never20
Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 1=Rarely00
Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 2=Occasionally01
Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 3=Frequently00
Sad or Unhappy Feelings, Pre-IDS Evaluation, Frequency, 4=Almost constantly00
Sad or Unhappy Feelings, End Of Treatment, Severity, 0=None—1
Sad or Unhappy Feelings, End Of Treatment, Severity, 1=Mild—1
Sad or Unhappy Feelings, End Of Treatment, Severity, 2=Moderate—0
Sad or Unhappy Feelings, End Of Treatment, Severity, 3=Severe—0
Sad or Unhappy Feelings, End Of Treatment, Severity, 4=Very severe—0
Sad or Unhappy Feelings, End Of Treatment, Frequency, 0=Never—3
Sad or Unhappy Feelings, End Of Treatment, Frequency, 1=Rarely—2
Sad or Unhappy Feelings, End Of Treatment, Frequency, 2=Occasionally—0
Sad or Unhappy Feelings, End Of Treatment, Frequency, 3=Frequently—0
Sad or Unhappy Feelings, End Of Treatment, Frequency, 4=Almost constantly—0
SecondaryNumber of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5

The FACT-GP5 item is a single item from the FACT-G that assesses how bothersome the side effects of treatment are for participants with cancer. It evaluates the extent to which side effects of treatment are bothersome for cancer participants. This outcome is measured using a 5-category response scale, where responses include 0="Not at all," 1="A little bit," 2="Somewhat," 3="Quite a bit," and 4="Very much." A higher score on this measure indicates that the participant experiences a greater level of bother from the side effects of treatment.

Time frame:
Baseline (Predose), Day 8 and 15 of Cycle 1; Day 1, 8, and 15 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Overall Side Effect Bother as Measured by Functional Assessment of Cancer Therapy - Item FACT-GP5
ParticipantsPlatinum-taxaneNiraparib
Baseline, 0=Not at all44
Baseline, 1=A little bit46
Baseline, 2=Somewhat17
Baseline, 3=Quite a bit40
Baseline, 4=Very much10
Cycle 1 Day 8, 0=Not at all02
Cycle 1 Day 8, 1=A little bit25
Cycle 1 Day 8, 2=Somewhat27
Cycle 1 Day 8, 3=Quite a bit61
Cycle 1 Day 8, 4=Very much10
Cycle 1 Day 15, 0=Not at all45
Cycle 1 Day 15, 1=A little bit22
Cycle 1 Day 15, 2=Somewhat47
Cycle 1 Day 15, 3=Quite a bit20
Cycle 1 Day 15, 4=Very much20
Cycle 2 Day 1, 0=Not at all45
Cycle 2 Day 1, 1=A little bit42
Cycle 2 Day 1, 2=Somewhat25
Cycle 2 Day 1, 3=Quite a bit12
Cycle 2 Day 1, 4=Very much00
Cycle 2 Day 8, 0=Not at all13
Cycle 2 Day 8, 1=A little bit43
Cycle 2 Day 8, 2=Somewhat36
Cycle 2 Day 8, 3=Quite a bit10
Cycle 2 Day 8, 4=Very much20
Cycle 2 Day 15, 0=Not at all24
Cycle 2 Day 15, 1=A little bit35
Cycle 2 Day 15, 2=Somewhat54
Cycle 2 Day 15, 3=Quite a bit21
Cycle 2 Day 15, 4=Very much10
Cycle 3 Day 1, 0=Not at all14
Cycle 3 Day 1, 1=A little bit93
Cycle 3 Day 1, 2=Somewhat46
Cycle 3 Day 1, 3=Quite a bit01
Cycle 3 Day 1, 4=Very much00
Cycle 3 Day 8, 0=Not at all11
Cycle 3 Day 8, 1=A little bit33
Cycle 3 Day 8, 2=Somewhat06
Cycle 3 Day 8, 3=Quite a bit50
Cycle 3 Day 8, 4=Very much10
Cycle 3 Day 15, 0=Not at all02
Cycle 3 Day 15, 1=A little bit32
Cycle 3 Day 15, 2=Somewhat13
Cycle 3 Day 15, 3=Quite a bit10
Cycle 3 Day 15, 4=Very much00
Pre-IDS Evaluation, 0=Not at all22
Pre-IDS Evaluation, 1=A little bit71
Pre-IDS Evaluation, 2=Somewhat64
Pre-IDS Evaluation, 3=Quite a bit00
Pre-IDS Evaluation, 4=Very much00
End Of Treatment, 0=Not at all—2
End Of Treatment, 1=A little bit—1
End Of Treatment, 2=Somewhat—2
End Of Treatment, 3=Quite a bit—0
End Of Treatment, 4=Very much—0
SecondaryChange From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire

EORTC IL136 includes items from the EORTC QLQ-C30, a 30-item survey assessing health-related quality of life (HRQoL) in cancer patients, featuring 5 functional scales, 3 symptom scales, 6 single items, and a global health status/HRQoL scale. Functional and symptom scales/items are rated on 4-point scale with options "Not at all," "A little," "Quite a bit," and "Very much". 2 items measuring global health status/quality of life use a 7-point scale ranging from 1 ("Very Poor") to 7 ("Excellent"). Each item has a specific scoring system, and scores were transformed to a 0-100 scale, where higher scores on functional scales and global health status/HRQoL scale indicate better functioning or quality of life, while higher scores on symptom scales/items indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to Cycle 1 Day 1 (C1D1), including those from unscheduled visits.

Time frame:
Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Reported as:
Mean · Scores on scale
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 136 (EORTC IL136) Questionnaire
Scores on scalePlatinum-taxaneNiraparib
Global Health Status/QoL, CFB to CYCLE 2 DAY 10.00 ± 19.3653.79 ± 27.224
Global Health Status/QoL, CFB to CYCLE 3 DAY 17.64 ± 16.46010.19 ± 38.814
Global Health Status/QoL, CFB to Pre-IDS EVALUATION-4.17 ± 22.3499.72 ± 27.597
Global Health Status/QoL, CFB to END OF TREATMENT—-23.33 ± 23.863
Rate Your Overall Health, CFB to CYCLE 2 DAY 1-1.52 ± 22.9184.55 ± 27.979
Rate Your Overall Health, CFB to CYCLE 3 DAY 19.72 ± 16.6039.26 ± 40.062
Rate Your Overall Health, CFB to Pre-IDS EVALUATION-4.76 ± 23.95611.11 ± 29.187
Rate Your Overall Health, CFB to END OF TREATMENT—-20.00 ± 18.257
Rate Your Overall Quality of Life, CFB to CYCLE 2 DAY 11.52 ± 18.9363.03 ± 28.692
Rate Your Overall Quality of Life, CFB to CYCLE 3 DAY 15.56 ± 19.24511.11 ± 38.188
Rate Your Overall Quality of Life, CFB to Pre-IDS EVALUATION-3.57 ± 21.8578.33 ± 27.386
Rate Your Overall Quality of Life, CFB to END OF TREATMENT—-26.67 ± 32.489
Physical Functioning Scale, CFB to CYCLE 2 DAY 10.61 ± 13.1507.27 ± 12.808
Physical Functioning Scale, CFB to CYCLE 3 DAY 11.53 ± 12.70210.37 ± 16.025
Physical Functioning Scale, CFB to Pre-IDS EVALUATION-1.43 ± 10.83814.44 ± 20.403
Physical Functioning Scale, CFB to END OF TREATMENT—-9.33 ± 17.385
Trouble Doing Strenuous Activity, CFB to CYCLE 2 DAY 10.00 ± 21.0823.03 ± 27.707
Trouble Doing Strenuous Activity, CFB to CYCLE 3 DAY 1-2.78 ± 9.62322.22 ± 23.570
Trouble Doing Strenuous Activity, CFB to Pre-IDS EVALUATION-7.14 ± 19.29822.22 ± 34.427
Trouble Doing Strenuous Activity, CFB to END OF TREATMENT—0.00 ± 33.333
Have Trouble Taking a Long Walk, CFB to CYCLE 2 DAY 10.00 ± 21.08221.21 ± 30.814
Have Trouble Taking a Long Walk, CFB to CYCLE 3 DAY 113.89 ± 30.01111.11 ± 28.868
Have Trouble Taking a Long Walk, CFB to Pre-IDS EVALUATION4.76 ± 22.10022.22 ± 34.427
Have Trouble Taking a Long Walk, CFB to END OF TREATMENT—-6.67 ± 14.907
Have Trouble Taking Short Walk, CFB to CYCLE 2 DAY 16.06 ± 20.1019.09 ± 15.570
Have Trouble Taking Short Walk, CFB to CYCLE 3 DAY 10.00 ± 33.3337.41 ± 14.699
Have Trouble Taking Short Walk, CFB to Pre-IDS EVALUATION-4.76 ± 17.81716.67 ± 27.889
Have Trouble Taking Short Walk, CFB to END OF TREATMENT—-13.33 ± 18.257
Stay in Bed or Chair During Day, CFB to CYCLE 2 DAY 1-3.03 ± 17.9790.00 ± 25.820
Stay in Bed or Chair During Day, CFB to CYCLE 3 DAY 1-2.78 ± 22.2857.41 ± 22.222
Stay in Bed or Chair During Day, CFB to Pre-IDS EVALUATION0.00 ± 18.4900.00 ± 21.082
Stay in Bed or Chair During Day, CFB to END OF TREATMENT—-13.33 ± 18.257
Need Help Eating Dressing Washing, CFB to CYCLE 2 DAY 10.00 ± 0.0003.03 ± 17.979
Need Help Eating Dressing Washing, CFB to CYCLE 3 DAY 10.00 ± 0.0003.70 ± 20.031
Need Help Eating Dressing Washing, CFB to Pre-IDS EVALUATION0.00 ± 0.00011.11 ± 17.213
Need Help Eating Dressing Washing, CFB to END OF TREATMENT—-13.33 ± 18.257
Social Functioning Scale, CFB to CYCLE 2 DAY 113.64 ± 27.7077.58 ± 36.027
Social Functioning Scale, CFB to CYCLE 3 DAY 113.89 ± 30.8411.85 ± 22.737
Social Functioning Scale, CFB to Pre-IDS EVALUATION7.14 ± 27.5148.33 ± 25.276
Social Functioning Scale, CFB to END OF TREATMENT—3.33 ± 18.257
Cond Interfere With Family Life, CFB to CYCLE 2 DAY 118.18 ± 31.1406.06 ± 44.267
Cond Interfere With Family Life, CFB to CYCLE 3 DAY 113.89 ± 33.207-7.41 ± 27.778
Cond Interfere With Family Life, CFB to Pre-IDS EVALUATION14.29 ± 36.314-5.56 ± 38.968
Cond Interfere With Family Life, CFB to END OF TREATMENT—-6.67 ± 27.889
Cond Interfere Social Activity, CFB to CYCLE 2 DAY 19.09 ± 30.1519.09 ± 33.635
Cond Interfere Social Activity, CFB to CYCLE 3 DAY 113.89 ± 30.01111.11 ± 28.868
Cond Interfere Social Activity, CFB to Pre-IDS EVALUATION0.00 ± 26.14922.22 ± 17.213
Cond Interfere Social Activity, CFB to END OF TREATMENT—13.33 ± 18.257
Dyspnea Symptom Scale, CFB to CYCLE 2 DAY 1-3.03 ± 10.0503.03 ± 17.979
Dyspnea Symptom Scale, CFB to CYCLE 3 DAY 10.00 ± 14.2130.00 ± 28.868
Dyspnea Symptom Scale, CFB to Pre-IDS EVALUATION0.00 ± 13.0740.00 ± 47.140
Dyspnea Symptom Scale, CFB to END OF TREATMENT—6.67 ± 27.889
Were You Short of Breath, CFB to CYCLE 2 DAY 1-3.03 ± 10.0503.03 ± 17.979
Were You Short of Breath, CFB to CYCLE 3 DAY 10.00 ± 14.2130.00 ± 28.868
Were You Short of Breath, CFB to Pre-IDS EVALUATION0.00 ± 13.0740.00 ± 47.140
Were You Short of Breath, CFB to END OF TREATMENT—6.67 ± 27.889
SecondaryChange From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire

The OC module (QLQ-OV28) supplements the QLQ-C30 and was designed for participants with local or advanced disease who receive treatment by surgery with or without chemotherapy. It consists of 28 items including 3 functional scales (body image, sexuality, attitude to disease/treatment burden) and 5 symptom scales/items (abdominal/gastrointestinal symptoms, peripheral neuropathy, hormonal/menopausal symptoms, other chemotherapy side effects, and hair loss). A subset of 9 questions will be utilized for this cohort, referred to as the EORTC IL137. The scoring approach is identical to the EORTC QLQ-C30. Scores are transformed to a 0-100 scale, where higher functional scale scores indicate better functioning, and higher symptom scale scores indicate greater symptom burden. Baseline is defined as the latest assessment with a non-missing value prior to C1D1, including unscheduled visits.

Time frame:
Baseline (Predose), Day 1 of Cycle 2 and Cycle 3; Pre-IDS Evaluation, and End of Treatment (Up to approximately 154 weeks).
Reported as:
Mean · Scores on scale
Change From Baseline (CFB) in European Organisation for Research and Treatment of Cancer Item Library 137 (EORTC IL137) Questionnaire
Scores on scalePlatinum-taxaneNiraparib
Felt physically Less Attractive, CFB to CYCLE 2 DAY 1-2.78 ± 17.164-3.33 ± 33.148
Felt physically Less Attractive, CFB to CYCLE 3 DAY 1-2.78 ± 33.2077.41 ± 52.116
Felt physically Less Attractive, CFB to Pre-IDS EVALUATION0.00 ± 18.490-16.67 ± 27.889
Felt physically Less Attractive, CFB to END OF TREATMENT—13.33 ± 38.006
Disease Burden, CFB to CYCLE 2 DAY 15.56 ± 19.24510.00 ± 27.442
Disease Burden, CFB to CYCLE 3 DAY 111.11 ± 25.95014.81 ± 50.308
Disease Burden, CFB to Pre-IDS EVALUATION11.90 ± 24.8320.00 ± 42.164
Disease Burden, CFB to END OF TREATMENT—13.33 ± 44.721
Treatment Burden, CFB to CYCLE 2 DAY 1-8.33 ± 32.1773.33 ± 39.907
Treatment Burden, CFB to CYCLE 3 DAY 10.00 ± 24.6187.41 ± 32.394
Treatment Burden, CFB to Pre-IDS EVALUATION2.38 ± 27.62511.11 ± 27.217
Treatment Burden, CFB to END OF TREATMENT—13.33 ± 18.257
Bloated Feeling Abdomen, CFB to CYCLE 2 DAY 1-8.33 ± 35.176-10.00 ± 41.722
Bloated Feeling Abdomen, CFB to CYCLE 3 DAY 10.00 ± 42.640-14.81 ± 29.397
Bloated Feeling Abdomen, CFB to Pre-IDS EVALUATION0.00 ± 29.235-5.56 ± 49.065
Bloated Feeling Abdomen, CFB to END OF TREATMENT—6.67 ± 43.461
Change Bowel Habit, CFB to CYCLE 2 DAY 1-33.33 ± 34.8160.00 ± 41.574
Change Bowel Habit, CFB to CYCLE 3 DAY 1-13.89 ± 45.965-7.41 ± 22.222
Change Bowel Habit, CFB to Pre-IDS EVALUATION-16.67 ± 31.351-11.11 ± 40.369
Change Bowel Habit, CFB to END OF TREATMENT—-6.67 ± 14.907
Troubled Pass Flatulence, CFB to CYCLE 2 DAY 18.33 ± 25.126-3.33 ± 24.595
Troubled Pass Flatulence, CFB to CYCLE 3 DAY 1-2.78 ± 22.285-3.70 ± 35.136
Troubled Pass Flatulence, CFB to Pre-IDS EVALUATION7.14 ± 26.7260.00 ± 29.814
Troubled Pass Flatulence, CFB to END OF TREATMENT—-20.00 ± 29.814
Felt Full Quick after Begin Eat, CFB to CYCLE 2 DAY 1-13.89 ± 22.2850.00 ± 41.574
Felt Full Quick after Begin Eat, CFB to CYCLE 3 DAY 1-15.15 ± 22.918-14.81 ± 33.793
Felt Full Quick after Begin Eat, CFB to Pre-IDS EVALUATION-11.90 ± 28.0635.56 ± 25.092
Felt Full Quick after Begin Eat, CFB to END OF TREATMENT—-6.67 ± 59.628
Acid Indigestion or Heartburn, CFB to CYCLE 2 DAY 12.78 ± 17.164-3.33 ± 29.187
Acid Indigestion or Heartburn, CFB to CYCLE 3 DAY 15.56 ± 12.975-7.41 ± 32.394
Acid Indigestion or Heartburn, CFB to Pre-IDS EVALUATION7.14 ± 14.194-11.11 ± 27.217
Acid Indigestion or Heartburn, CFB to END OF TREATMENT—6.67 ± 27.889
Felt Weak in Your Arms or Legs, CFB to CYCLE 2 DAY 1-5.56 ± 19.245-6.67 ± 21.082
Felt Weak in Your Arms or Legs, CFB to CYCLE 3 DAY 118.18 ± 34.524-18.52 ± 33.793
Felt Weak in Your Arms or Legs, CFB to Pre-IDS EVALUATION4.76 ± 34.237-11.11 ± 34.427
Felt Weak in Your Arms or Legs, CFB to END OF TREATMENT—6.67 ± 27.889
SecondaryNumber of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose resulted in death, is life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, is a congenital anomaly/birth defect, other situations and is associated with liver injury or impaired liver function. SAEs are subsets of AEs. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.

Time frame:
Up to approximately 154 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent (TE) Non-serious Adverse Events (Non-SAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Treatment Emergent (TE) Special Interest (AESIs) by Severity
ParticipantsPlatinum-taxaneNiraparib
TE Non-SAEs1719
TESAEs42
TE AESIs00
SecondaryNumber of Participants With Dose Modification Due to TEAEs

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is an event that emerged during treatment having been absent pretreatment or worsened relative to the pretreatment state. Number of participants with dose modifications : permanent discontinuation, dose reduction and treatment interruption/delay due to AEs is summarized.

Time frame:
Up to approximately 154 weeks
Reported as:
Count of participants · Participants
Number of Participants With Dose Modification Due to TEAEs
ParticipantsPlatinum-taxaneNiraparib
Permanent Discontinuation54
Dose Reduction147
Treatment Interruption/delay1111

Adverse events

Collected over All-cause mortality, Treatment-Emergent Serious Adverse Events (TESAEs), and TE Non-SAEs were collected up to approximately 154 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Platinum-taxane4/17 (23.5%)4/17 (23.5%)17/17 (100%)
Niraparib4/19 (21.1%)2/19 (10.5%)19/19 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventPlatinum-taxaneNiraparib
Intestinal obstructionGastrointestinal disorders2/170/19
ThrombocytopeniaBlood and lymphatic system disorders1/170/19
Cardiac failureCardiac disorders1/170/19
Large intestine perforationGastrointestinal disorders1/170/19
General physical health deteriorationGeneral disorders1/170/19
Infusion related reactionInjury, poisoning and procedural complications1/170/19
Pelvic haematomaReproductive system and breast disorders1/170/19
HypotensionVascular disorders1/170/19
Febrile neutropeniaBlood and lymphatic system disorders0/171/19
Haemorrhagic strokeNervous system disorders0/171/19
Most frequent other events
Showing 10 of 207
Most frequent other events
EventPlatinum-taxaneNiraparib
FatigueGeneral disorders14/177/19
Neuropathy peripheralNervous system disorders13/171/19
AnaemiaBlood and lymphatic system disorders11/1710/19
NauseaGastrointestinal disorders11/174/19
ConstipationGastrointestinal disorders10/178/19
InsomniaPsychiatric disorders8/179/19
NeutropeniaBlood and lymphatic system disorders8/173/19
ThrombocytopeniaBlood and lymphatic system disorders8/175/19
Abdominal painGastrointestinal disorders8/176/19
VomitingGastrointestinal disorders8/174/19

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Platinum-taxaneNiraparibTotal
Mean61.0 ± 13.6758.4 ± 12.2659.6 ± 12.82
Sex: Female, Male
Sex: Female, Male(Participants)Platinum-taxaneNiraparibTotal
Female171936
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Platinum-taxaneNiraparibTotal
Hispanic or Latino134
Not Hispanic or Latino161632
08

Study locations

21 sites
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Tampa, Florida 33606, United States
  • GSK Investigational Site
    Scarborough, Maine 04074, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    St Louis, Missouri 63141, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    New York, New York 77030, United States
  • GSK Investigational Site
    Rochester, New York 14642, United States
  • GSK Investigational Site
    Sioux Falls, South Dakota 57105, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 0A9, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    A Coruña, ES 15006, Spain
  • GSK Investigational Site
    Madrid, ES 28027, Spain
  • GSK Investigational Site
    Madrid, ES 28033, Spain
  • GSK Investigational Site
    Madrid, ES 28050, Spain
  • GSK Investigational Site
    Madrid, ES 28223, Spain
  • GSK Investigational Site
    Málaga, ES 29001, Spain
  • GSK Investigational Site
    Pamplona, ES 31008, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Jun 2024, 26 months.

Results were first posted in Jul 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 9, 2025
StartActual
Apr 14, 2022
Primary completionActual
Jun 28, 2024
CompletionActual
Mar 31, 2025
Results first posted
Jul 15, 2025
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06964165
Lead sponsor
Tesaro, Inc.
Responsible party
Sponsor
First posted
May 9, 2025
Start date
Apr 14, 2022
Primary completion
Jun 28, 2024
Completion
Mar 31, 2025
Results posted
Jul 15, 2025
Last update
Nov 26, 2025

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Carboplatin · Paclitaxel

Start the discussion